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PREFACE 
Particle design for active pharmaceutical ingredients is of great interest in the pharmaceutical 
industry in recent years. In this paper, the following two separate approaches to the particle 
design are described; 
Part 1: Critical parameters of drug substance quality on processability of drug product 
manufacturing and on product quality 
Part 2: Micronization and polymorphic conversion of tolbutamide and barbital by rapid 
expansion of supercritical solutions 
In Part 1, drug substance quality determining flowability and dissolution behavior is discussed. 
In Part 2, one-step processing for micronization and polymorphic conversion is discussed. 
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PART 1: CRITICAL PARAMETERS OF DRUG SUBSTANCE QUALITY 
ON PROCESSABILITY OF DRUG PRODUCT MANUFACTURING AND 
ON PRODUCT QUALITY 
1. ABSTRACT 
Drug substance quality is sometimes crucial for the processability of drug product manufacturing 
and for the product quality, especially in the case of high drug loads. A tablet formulation of 
Compound-A, which is being developed for a cancer therapy, at a drug load of ca. 80 %, has 
successfully been developed based on fluidized bed granulation followed by the compression of 
resultant granules, using drug substances manufactured by Company-M (M-batches). Serious 
problems occurred when the manufacturing of the drug substances was transferred to Company-
S. 
• Drug substances manufactured by Company-S (S-batches) did not flow well during the 
granulation, which inhibited full-automation. 
• The granules were sometimes too bulky to apply to a tablet press. 
• The tablets showed relatively slow dissolution behavior when compared to those 
manufactured using M-batches. 
The aim of the present study was to clarify the critical parameters of drug substance quality 
determining flowability and dissolution behavior, in order to ensure the robust manufacturing 
processes and the constant quality. 
Four batches each of Compound-A from both companies were served for the investigation (intact 
samples). Furthermore, the best and the worst batches in respect of the powder flow were 
selected as typical M- and S-batches respectively, and both the hammer- and jet-milled samples 
were prepared, where the former processing is being employed for the actual drug product 
manufacturing to break coarse agglomerates and the latter was just for further characterization. 
Recrystallization of Compound-A was performed under various conditions to modify the crystal 
habit (shape and size). The drug substance was dissolved at a concentration of 30 mg/mL by 
heating to the boiling point of the crystallizing solvent. The solution was cooled down to 
precipitate under continuous agitation. The precipitate was isolated onto a 0.45-µm filter, and 
then dried at 50 °C for 6 h. The powder was sieved at a pore size of 1000 µm before the 
characterization. 
Angle of spatula, which is one of the tests for Carr’s flowability index, was applied to quantify 
the powder flow. To characterize the physicochemical properties, chemical purity (HPLC 
analysis), crystal form (X-ray powder diffractometry, differential scanning calorimetry, infrared 
spectrophotometry), surface charge (zeta potential measurement), particle size distribution (laser 
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diffractometry) and particle morphology (microscopy combined with image analysis) were 
investigated. Dissolution tests were performed according to the Paddle Method, JP14. 
All the intact S-batches were bulkier than intact M-batches and exhibited poorer powder flow. 
Unexpectedly, jet-milled samples showed good performance on powder flow. HPLC analysis 
clarified that there was no correlation between the chemical purity and flowability. X-ray powder 
diffractometry, differential scanning calorimetry and infrared spectroscopy demonstrated that 
there was no difference in the crystal form between M- and S-batches. Zeta potential 
measurement indicated that there was no significant difference in the surface charge between M- 
and S-batches, where the surface of Compound-A particles was positively charged at 
approximately 20 mV. A difference in particle size was found on laser diffractometry. The mean 
particle size of typical M- and S-batches was 25 µm and 7 µm, respectively (intact & hammer-
milled). The smaller particle size and therefore the larger surface area of S-batches could be a 
reason for the poor flowability. However, this assumption was contradictory to the better 
flowability of jet-milled samples, of which mean particle size was 4 µm. Microscopic 
observation revealed that there was a significant difference in particle shape between M- and S-
batches. Primary particles of M-batches were plate-shaped, while those of S-batches were mostly 
elongated (intact and hammer-milled). Image analysis proved the morphological difference. The 
elongation ratio (length divided by width) of primary particles of typical M- and S-batches was 
1.5 and 2.2, respectively, whereas jet-milled samples had similar elongation ratio to the M-batch 
(1.5 ~ 1.6). It was assumed that particle shape was the critical factor determining the powder 
flow of Compound-A. 
The influence of process variables during recrystallization on particle morphology and 
flowability was investigated as listed below; 
• Crystallizing solvent: Methanol, 50 % methanol or ethanol was used as the crystallizing 
solvent. As long as the cooling rate was rapid (ice water bath), all the solvents brought small 
plate-shaped particles, which formed firm agglomerates and exhibited good powder flow. 
Crystallizing solvent hardly affected the particle morphology and flowability. 
• Cooling rate: Rapid cooling, natural cooling (room temperature) and slow cooling (warm 
water bath) were compared using methanol as the crystallizing solvent. All the cooling rates 
brought plate-shaped particles. Faster cooling resulted in smaller primary particles, higher 
degree of agglomeration, and better powder flow. Cooling rate was an important variable 
relating to the primary particle size and flowability. 
• Seeding: 10 % equivalent of seeds was added before spontaneous nucleation during the 
cooling process (natural cooling) using methanol as the crystallizing solvent. Plate-shaped 
seeds brought slightly elongated particles, which formed agglomerates only in part and 
exhibited poor powder flow. Needle-shaped seeds brought perfect needles with no firm 
agglomerates, which showed extremely poor powder flow. Seeding induced nucleation and 
crystal growth at lower degree of the solute saturation, which would be favorable for the 
elongation of Compound-A crystals. 
• Washing with anti-solvent: Precipitate recovered on the filter was washed with n-hexane 
before the drying process (crystallizing solvent: methanol; cooling rate: rapid). This 
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additional processing should realize complete de-agglomeration before drying and also was 
expected to prevent aggregation and agglomeration during drying. However, this attempt had 
only slight effect; Most of the particles formed agglomerates again after drying. This 
agglomeration behavior was considered as an essential nature for plate-shaped particles of 
Compound-A. 
All the plate-shaped particles of Compound-A exhibited good powder flow. Since plates should 
contact with each other by face to face, firm agglomeration would occur. As a result, apparent 
particle size and density would increase. This means the decrease in surface area and 
compressibility, therefore the powder would exhibit good flowability. Among these batches, 
better flow was seen when the primary particles were smaller, where apparent particle size was 
inversely larger due to the higher degree of agglomeration. Adhesion force would be dominant 
over the separation force when particles were small. On the other hand, all the needle-shaped 
particles of Compound-A exhibited poor powder flow regardless of the primary particle size. 
They did not form firm agglomerates because the contact between these particles should be point 
to point. As a result, apparent particle size would be the same as primary particle size itself. 
Small particle size and low apparent density mean high surface area and compressibility, 
therefore the powder would exhibit poor flowability. 
Tablets made from the typical S-batch showed lower dissolution rates than those done from the 
typical M-batch throughout the dissolution test. Contrary to expectations, powder dissolution of 
the S-batch was more rapid than that of the M-batch, probably due to the larger surface area. 
However, the relationship found in the drug products could be reproduced by adding the 
excipient; The powder dissolution of the M-batch was improved but that of the S-batch was 
delayed when they were mixed with lactose (monohydrate, milled), a main component of the 
drug product. Microscopic observation revealed that the relative particle size of Compound-A to 
the excipient was responsible for the dissolution behavior. The particle size of lactose was 
roughly half of the M-batch and twice that of the S-batch. Lactose particles adhered to the 
surface of M-batch particles when mixed. On the other hand, most of the lactose particles were 
covered with S-batch particles. Lactose is well known to have wetting effect, and therefore the 
dissolution behavior of Compound-A should depend on whether or not lactose could be on the 
surface of individual particles. Since the apparent particle size of M-batches were large due to 
the high degree of agglomeration as well as the original primary particle size, lactose particles 
always existed on the surface of M-batch particles, where the improvement on wettability by 
lactose could be expected. On the other hand, S-batches could not receive benefit from lactose 
because of the small apparent particle size. Furthermore, agglomeration occurred due to the 
relatively slow dissolution kinetics of lactose, and thus the dissolution of Compound-A was 
delayed. 
It can be concluded that particle shape is the critical factor determining the powder flow of 
Compound-A. As illustrated in Figure 1, plate-like shape facilitates firm agglomeration and 
results in good powder flow, unlike needle-like shape. The relative particle size of Compound-A 
to other excipients is considered responsible for the dissolution behavior. Although 
recrystallization studies reported herein were not necessarily comprehensive, it is 
recommendable that rapid cooling should be employed to promote agglomeration. Even more 
importantly, complete dissolution of starting material before cooling has to be assured to avoid 
producing elongated particles, which would exhibit poor powder flow. 
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Figure 1 Influence of particle shape on flowability of Compound-A powders. 
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2. INTRODUCTION 
Drug substance quality is sometimes crucial for the processability of drug product manufacturing 
and for the product quality. Especially in the case of drugs that require being administered in 
high doses, the amount of excipients should be kept down 1, where even a small difference in the 
physicochemical and mechanical properties of drug substances could have a great impact on the 
processability and performance of dosage forms. 
Polymorphism, which is the definite arrangement of molecules within a solid, is well known to 
influence various physicochemical, mechanical and biological properties, and that is also true for 
crystal habit. Crystal habit is the outer appearance of a crystal and is described by its shape and 
size. Different habits may be produced when the environment of a growing crystal affects its 
external shape without changing its internal structure, polymorphic form. The alteration in habit 
is caused by the interference with the uniform approach of crystallizing molecules to different 
faces of a growing crystal 2. Different polymorphic forms or crystal habits of a particular drug 
possess different planes and thus differ in their free surface energy. Therefore, they may exhibit 
different properties such as dissolution rate, powder flow, and compressibility, which are of 
pharmaceutical interest 3. 
The impact of the crystal habit of active pharmaceutical ingredients on the mechanical properties 
was reported on nitrofurantoin (compaction properties: tabular vs. needle-like 4, 5), paracetamol 
(tableting behavior: plate-shaped vs. prismatic 1; compression properties: prismatic polyhedral vs. 
thin plate-like 6), mefenamic acid (easiness to handle in a granulation process 7), ibuprofen 
(tableting behavior: plate-shaped vs. needle-shaped 1; bulk density, flowability & compression 
force–hardness profiles: polyhedral, needle-like vs. elongated 3; compression & densification 
behavior: stick-shaped, acicular vs. polyhedral 8 ; flowability & dissolution behavior: cubic, 
needle-shaped, plate-shaped vs. spherical agglomerates 9 ), L-lysine monohydrochloride 
dihydrate (tabletability: prism-shaped vs. plate-shaped 10) and phenytoin (dissolution behavior & 
compaction properties: thin plate, needle shape vs. rhombic 11). 
Special techniques such as spherical crystallization 12, phase partition 13 and incorporation of 
additives 14, 15 offer the modification of crystal habit. However, these approaches are possible 
only when the development is still in the early stage, or bioequivalency could be kept against 
former drug products that have been applied to the clinical trials. 
Crystallization is commonly employed as the final step for the purification of active 
pharmaceutical ingredients. Different crystallization conditions may alter the polymorphic form 
and/or crystal habit. Many factors are known to influence the crystallization process; e.g. degree 
of supersaturation, rate of cooling, degree of solution agitation, nature of solute, nature of 
crystallizing solvent, and presence of impurities 2. Even if the crystallization conditions are 
regarded as the same, different crystals could be produced when different crystallizers are 
employed to scale up the process or to transfer it to another plant. 
A tablet formulation of Compound-A, which is being developed for a cancer therapy, at a drug 
load of ca. 80 %, has successfully been developed based on fluidized bed granulation followed 
by the compression of resultant granules, using drug substances manufactured by Company-M 
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(M-batches). Serious problems occurred when the manufacturing of the drug substances was 
transferred to Company-S. Drug substances manufactured by Company-S (S-batches) did not 
flow well during the granulation, which inhibited full-automation. The granules were sometimes 
too bulky to apply to a tablet press. Furthermore, the tablets showed relatively slow dissolution 
behavior when compared to those manufactured using M-batches. 
The aim of the present study was to clarify the critical parameters of drug substance quality 
determining flowability and dissolution behavior, in order to ensure the robust manufacturing 
processes and the constant quality. 
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3. MATERIALS AND METHODS 
3.1 Materials 
Test batches are shown in Table 1. Four batches each of Compound-A from both companies 
were served for the investigation (intact samples). Furthermore, the best and the worst batches in 
respect of the powder flow were selected as typical M- and S-batches respectively (M4 & S4), 
and both the hammer- and jet-milled samples were prepared, where the former processing is 
being employed for the actual drug product manufacturing to break coarse agglomerates and the 
latter was just for further characterization. The appearance of typical Compound-A batches is 
presented in Figure 2. All the intact and hammer-milled S-batches were bulky, poorly flowing, 
easily charged, adhesive powders when compared to M-batches, while jet-milled samples were 
even better. 
Table 1 Test batches of Compound-A from Company-M (M-batches) & Company-S (S-batches). 
Test batches Hammer-milled c Jet-milled d
M-batches M1, M2, M3, M4 a M4 (H) M4 (J)
S-batches S1, S2, S3, S4 b S4 (H) S4 (J)
Intact
 
a the best batch in respect of the powder flow (typical M-batch). 
b the worst batch in respect of the powder flow (typical S-batch). 
c Sample-mill, KIII-1 (Fuji Paudal Co., Ltd., Osaka, Japan), equipped with a 2-mm screen, operated at 11,000 rpm. 
d Co-jet, alpha (Seishin Enterprise Co., Ltd., Tokyo, Japan), operated at 5 kgf/cm2. 
 
Intact Hammer-milled Jet-milled
M4 M4 (H) M4 (J)
S4 (J)S4 (H)S4
 
Figure 2 Appearance of typical Compound-A batches. Sample size: 10 g. 
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Lactose (Pharmatose 450M: monohydrate, milled) was purchased from DMV International 
(Veghel, The Netherlands). Potassium bromide was of infrared spectrophotometry grade 
(Nacalai Tesque, Inc., Kyoto, Japan), and pretreated according to the Japanese Pharmacopoeia 
before use. Methanol, ethanol, n-hexane, and liquid paraffin were of reagent grade, and used as 
received. Acetonitrile was of gradient grade for liquid chromatography (Merck KGaA, 
Darmstadt, Germany). Hydrochloric acid, 1 mol/L (factor = 1.005 at 20 °C) was purchased from 
Kanto Chemical Co., Inc. (Tokyo, Japan). Water, used for HPLC analysis, was prepared in-
house by using NANOpure DiamondTM (Barnstead International, MA, USA). Water, used for 
zeta potential measurement, was of HPLC grade (Nacalai Tesque, Inc., Kyoto, Japan). Water, 
used for preparing 50 % methanol on recrystallization, was prepared in-house by using Autopure 
WEX3 (Millipore Corporation, MA, USA). Water, used for dissolution tests, was prepared in-
house by using DiamondTM RO (Barnstead International, MA, USA) or Milli-RX45 (Millipore 
Corporation, MA, USA). 
3.2 Recrystallization 
Recrystallization of Compound-A was performed under various conditions to modify the crystal 
habit (shape and size). The flow chart and process variables are shown in Figure 3. The drug 
substance was dissolved at a concentration of 30 mg/mL by heating to the boiling point of the 
crystallizing solvent. Methanol, 50 % methanol or ethanol was used as the crystallizing solvent 
since only these solvents could dissolve Compound-A completely at the conditions mentioned 
above among all the solvents which were known not to induce another polymorph or solvate. 
The solution was cooled down to precipitate under continuous agitation. Rapid cooling (ice 
water bath), natural cooling (room temperature) or slow cooling (warm water bath) was applied. 
The precipitate was isolated onto a 0.45-µm filter (surfactant free cellulose acetate, Nalge Nunc 
International, NY, USA), and then dried at 50 °C for 6 h. The powder was sieved at a pore size 
of 1000 µm (JIS Z 8801, Tokyo Screen Co., Ltd., Tokyo, Japan) before the characterization. 
The influence of seeding during natural cooling was investigated; 10 % equivalent of plate- or 
needle-shaped seeds was added at about 40 °C, which was roughly 10 °C above the temperature 
where spontaneous nucleation would occur. The influence of washing with anti-solvent before 
the drying process was also investigated; Precipitate recovered on the filter was washed with n-
hexane to de-agglomerate individual particles. 
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Methanol 50 % Methanol Ethanol
Rapid Natural Slow
(ice water bath, 2 h) (RT, 2 h) (warm water bath, 12 h)
None n-Hexane (iced)
Crystallizing solvent
Plate-shaped d Needle-shaped e
Drying (50 °C, 6 h)
(30 mg/mL a , boiling point b )
(continuous agitation)
(10 % equivalent, ca. 40 °C c )
Seeding
Compound-A
Dissolution
Powder
Cooling
None
Sieving (< 1000 µm)
Isolation (0.45-µm filter)
Washing
 
Figure 3 Flow chart & process variables for recrystallization of Compound-A. a 1.5 g per 50 mL or 
15 g per 500 mL. b 65 °C (methanol & 50 % methanol) or 78 °C (ethanol). c added before 
spontaneous nucleation. d M4 (J): elongation ratio = 1.5, mean particle size = 4 µm. e S4 (H): 
elongation ratio = 2.3, mean particle size = 7 µm. 
 
3.3 Physicochemical and mechanical properties 
3.3.1 Powder flow 
Flow properties specified by Carr 16  (angle of repose, compressibility, angle of spatula & 
cohesion) were evaluated to quantify the powder flow of Compound-A batches using Powder 
Tester, PT-N (Figure 4: Hosokawa Micron Corporation, Osaka, Japan) under the standard 
operation conditions. Giving point scores to each flow property, Carr’s flowability index was 
calculated. 
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b-1 b-2
b-3 b-4
c-1 c-2
c-3 c-4
a-1 a-2 d-1 d-2
b) Compressibility c) Angle of spatula
Powder Tester, PT-N
a) Angle of repose d) Cohesion
d-3
 
Figure 4 Powder Tester, PT-N. a) Angle of repose. a-1: measurement unit. a-2: a heap of a powder, built 
up on a horizontal platform. b) Compressibility (bulk & tapped densities). b-1: measurement unit. 
b-2: a powder, filled in a 100-mL cup. b-3: after leveling off an excess of the powder. b-4: a 
powder, filled in a 100-mL cup equipped with the extension. c) Angle of spatula. c-1: 
measurement unit. c-2: a powder, loaded on a blade in a pan. c-3: after spooning up the powder 
on the blade. c-4: lifting up a bushing to a constant height to give an impact to the powder. d) 
Cohesion. d-1: measurement unit. d-2: a 2.0-g powder, applied to the top of three sieves. d-3: 
after the vibration. 
 
Angle of repose: Angle of repose is the angle between the horizontal and the slope of a heap of a 
material which has been dropped from some elevation. Angle of repose is a direct indication of 
potential flowability; Higher degrees of the angle of repose suggest less flowability of the 
material. The angle of repose of Compound-A batches was measured by allowing the powder to 
fall through a 1000-µm sieve and a glass funnel for about 180 s onto a horizontal platform to 
build up a heap having a constant slope. Vibration was adjusted to facilitate the powder flowing 
through the funnel. 
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Bulk density: Bulk density is the weight per unit volume of a material which has been loosely 
filled in a container. The bulk density of Compound-A batches was measured by allowing the 
powder to fall through a 1000-µm sieve and to fill into a 100-mL cup. Vibration was adjusted to 
fill up the cup with the powder about 30 s after the initiation. An overflow of the powder was 
leveled off and the net weight of the powder in the cup was used for the calculation (constant 
volume method). In the case of recrystallized batches, the test was performed with a 30-mL cup 
instead of the 100-mL cup (batch size: 15 g), or performed according to the constant mass 
method with 1 g of powders and a 10-mL graduated glass cylinder, readable to 0.1 mL (batch 
size: 1.5 g). 
Tapped density: Tapped density is the weight per unit volume of a material which has been filled 
in a container with tapping. Attaching a cup extension over the cup after the bulk density 
measurement, the tapped density of Compound-A batches was measured by tapping 180 times at 
an 18-mm stroke. An excess of the powder was leveled off and the net weight of the powder in 
the cup was used for the calculation (constant volume method). 
Compressibility: Compressibility is a flow characteristic of a material calculated from bulk and 
tapped densities (Equation [1]); Higher percentage of compressibility suggests less flowability of 
the material. The borderline between free-flowing and non-free-flowing is about 20 to 21 % 
compressibility. 
Compressibility [%] = ( P – A ) / P x 100 [1] 
P: tapped density [g/mL] 
A: bulk density [g/mL] 
Angle of spatula: Angle of spatula is the angle between the horizontal and the slope of a material 
which has been spooned up on a blade. Angle of spatula gives a broader spectrum on flowability 
than angle of repose since, in general, angle of spatula is always higher than angle of repose for a 
given material; Higher degrees of the angle of spatula suggest less flowability of the material. 
For a material to be considered free flowing, its angle of spatula should be less than 40 degrees. 
The angle of spatula of Compound-A batches was measured by inserting a blade into the powder, 
which had been passed through a 1000-µm sieve, on a pan and then lifting the blade up above 
the powder loaded. A bushing was dropped from a constant height once. The average of the two 
angles before and after the impact was employed as the angle of spatula. 
Cohesion: Cohesion is the degree of agglomerates measured by sieving. Cohesion is a flow 
characteristic of a material and is a direct determination of the energy necessary to pull apart 
agglomerates of cohesive particles in a specific time; Higher percentage of cohesion suggests 
less flowability of the material. The cohesion of Compound-A batches was measured by 
applying a 2.0-g powder, which had been passed through a 1000-µm sieve, to the top of three 
sieves under 1-mm amplitude of vibration. Based on the bulk and tapped densities, the 
combination of sieves and vibration time were selected. 
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Combination of sieves for cohesion; 
Average bulk density a Top sieve Center sieve Bottom sieve 
< 0.4 g/mL 350 µm 250 µm 150 µm 
0.4 – 0.9 g/mL 250 µm 150 µm 75 µm 
> 0.9 g/mL 150 µm 75 µm 45 µm 
a ( Bulk density + Tapped density ) / 2. 
Vibration time for cohesion; 
Vibration time [s] = 20 + { ( 1.6 – W ) / 0.016 } [2] 
W = ( P – A ) x C + A [3] 
W: working bulk density [g/mL] 
P: tapped density [g/mL] 
A: bulk density [g/mL] 
C: compressibility in fraction 
If W is greater than 1.6, the vibration time becomes equal to 20 s. 
Calculation of cohesion; 
Cohesion [%] 
= ( WT / 2 ) x 100 + ( WC / 2 ) x 100 x (3/5) + ( WB / 2 ) x 100 x (1/5) [4] 
WT: weight of the powder left on the top sieve [g] 
WC: weight of the powder left on the center sieve [g] 
WB: weight of the powder left on the bottom sieve [g] 
3.3.2 Chemical purity 
HPLC analysis of Compound-A batches was performed to investigate the chemical purity in 
respect of related substances. About 30 mg of Compound-A was dissolved in a mixture of water, 
acetonitrile and 1 mol/L hydrochloric acid (75:25:4) by using ultrasound to make exactly 25 mL, 
and this solution was used as the sample solution (1.2 mg/mL). The test was performed with 5 
µL of the sample solution by using a HPLC system, composed of a system controller SCL-10AVP, 
a degasser DGU-14A, 2 sets of pumps LC-10ADVP, an auto injector SIL-10ADVP, a column 
oven CTO-10ACVP, and a UV-VIS detector SPD-10AVVP (Shimadzu Corporation, Kyoto, 
Japan). The operating conditions were as follows; detection = UV 220 nm, column = 
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Hydrosphere 3 µm, 4.6 x 150 mm (YMC Co., Ltd., Kyoto, Japan), column temperature = 20 °C, 
mobile phase A = water + 1 mol/L HCl (25 + 1), mobile phase B = acetonitrile, and flow rate = 1 
mL/min. 
Time  
[min] 
Mobile phase A
[%] 
Mobile phase B
[%] 
0 – 25 95 → 65 5 → 35 
25 – 48 65 → 15 35 → 85 
48 – 50 15 85 
50 – 52 15 → 95 85 → 5 
52 – 60 95 5 
 
The area of each peak other than the peak of the free acid of Compound-A was determined by 
the automatic integration method (CLASS-VP, version 5.032, Shimadzu Corporation, Kyoto, 
Japan), and each amount was calculated in area percent. 
3.3.3 Crystal form 
X-ray powder diffractometry (XRPD): The crystal form of Compound-A batches was 
investigated by an X-ray powder diffractometer (PowderMini, Rigaku Corporation, Tokyo, 
Japan) equipped with a Ni-filtered Cu-anode (A-20Cu, Toshiba Corporation, Tokyo, Japan; 30 
kV, 15 mA). Specimens were gently ground by using an agate mortar and filled (intact: 300 mg) 
or were directly filled (hammer-milled: 300 mg; jet-milled: 200 mg) in a sample plate (24-mm 
diameter x 2-mm depth). The XRPD patterns were recorded at a scanning speed of 2θ = 1 °/min 
(step width: 2θ = 0.01 °) over a range of 2θ = 2 – 30 °. 
Differential scanning calorimetry (DSC): Supplemental evidence on crystal form was taken 
with a differential scanning calorimeter (DSC6200, Seiko Instruments Inc., Chiba, Japan). About 
5 mg of specimens were filled in a crimped aluminum pan and the DSC traces were recorded at a 
heating rate of 5 °C/min (sampling interval: 0.5 s) over a range of 25 – 300 °C under the nitrogen 
atmosphere flowing at 60 mL/min. The melting temperature (onset & peak) and the heat of 
fusion were calculated. 
Infrared spectrophotometry (IR): Supplemental evidence on crystal form was also taken with a 
Fourier transform infrared spectrometer (FT/IR-230, Jasco Corporation, Tokyo, Japan). 
According to the potassium bromide disk method, about 1 mg of specimens and 200 mg of 
potassium bromide were co-ground by using an agate mortar (0.5 %) and a part of the mixture 
was compressed (Mini Press, MR-1, Jasco Corporation, Tokyo, Japan). The infrared spectra 
were recorded over a range of 4000 – 400 cm-1. The FT-integration was set at 32 times. 
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3.3.4 Surface charge 
Zeta potential of Compound-A particles was measured to investigate the surface charge. For this 
purpose, only jet-milled samples (i.e. not intact or hammer-milled samples) were applicable 
considering the particle size. Compound-A was dispersed in the 0.45-µm filtrate of Compound-A 
saturated water (saturation concentration: ca. 2 mg/mL at room temperature) at a concentration 
of 200 µg/mL, and the power spectra were recorded by using an electrophoretic light scattering 
spectrophotometer (NICOMPTM, 380ZLS, Particle Sizing Systems, CA, USA). The operating 
conditions were as follows; laser wavelength = 532 nm, scattering angle = 14.1 °, electrical field 
= 10 V/cm, channel width = 500 µs, temperature = 23 °C, and run time = 1.0 ± 0.5 min. 
3.3.5 Particle size distribution 
Laser diffractometry under wet dispersion was performed to investigate the particle size 
distribution patterns of Compound-A. Appropriate amounts (10 – 50 mg) of specimens were 
dispersed in the medium, 0.45-µm filtrate of Compound-A saturated n-hexane (saturation 
concentration: ca. 10 µg/mL at room temperature), and the particle size based on the volume 
distribution was measured by using a laser diffractometer (Microtrac FRA, Nikkiso Co., Ltd., 
Tokyo, Japan), ranging 0.1 – 700 µm. Compound-A was dispersed by the following two 
different methods to estimate the binding strength of the agglomerates; 
• “sonicated”: measured after 3-minutes’ sonication in the medium. 
• “stirred”: measured periodically under continuous stirring in the medium (no pretreatment). 
Particle size distribution patterns of some batches shifted to lower range depending on the 
sonication time, and 3-minutes’ sonication could achieve the convergence. Therefore, particle 
size distribution patterns under “sonicated” can be considered as the figure after de-
agglomeration, and those under “stirred” show the course of de-agglomeration. 
3.3.6 Particle morphology 
Microscopic observation of Compound-A batches was performed to investigate the crystal habit. 
The shape and surface texture of the particles were examined by a scanning electron microscope, 
JSM-T20 (Jeol Ltd., Tokyo, Japan) or VE-8800 (Keyence Corporation, Osaka, Japan). 
Specimens were mounted on a metal stub with a conductive double-sided adhesive tape, and in 
the case of JSM-T20, were gold-coated under vacuum with a layer of approximately 400 Å 
thickness (1.2 kV, 5 – 10 mA, 10 min) by an ion sputter (JFC-1100, JEOL Ltd., Tokyo, Japan). 
Separately, image analysis was performed to study the particle shape thoroughly. Specimens 
were mounted on a glass slide and dispersed by appropriate use of air spray, or were dispersed in 
liquid paraffin at a concentration of 5 mg/mL. Several photographs from different portions were 
taken by using a digital microscope, VHX-100 equipped with a zoom lens, VH-Z450 (Keyence 
Corporation, Osaka, Japan) or by using an optical microscope, BX50 equipped with a digital 
camera, PDMC Ie/OL (Olympus Corporation, Tokyo, Japan) so as to analyze at least 1000 
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particles per batch, where the sample size was determined to achieve an accuracy of 0.05 for 
elongation ratio from a preliminary result obtained with 100 particles, referring to a method 
proposed by Larsen et al. 17 . The magnification was selected based on the mean diameter 
measured by laser diffractometry, referring to the minimum resolution proposed by Podczeck et 
al. 18; 0.425 µm per pixel for M4 and M4 (H), 0.193 µm per pixel for S4 and S4 (H), 0.091 µm 
per pixel for M4 (J) and S4 (J), and 0.158 µm per pixel for R10 ~ R13. Outlines of primary 
particles were manually traced one by one, and the dimensions were calculated by using an 
image analysis software, Win ROOF, version 3.51 (Mitani Corporation, Fukui, Japan) as the 
following shape descriptors; circle equivalent diameter (Equation [5]), circularity (Equation [6]), 
length (maximum Feret diameter), width (Feret diameter perpendicular to the length) and 
elongation ratio (length divided by the width). 
A
Circle equivalent diameter = 2 √
π
[5]
4 π A
Circularity = 
P2 
(0 < Circularity ≤ 1) [6]
A: projected area 
P: perimeter 
3.3.7 Dissolution behavior 
The dissolution test of Compound-A, 300 mg equivalent, was performed at 50 rpm according to 
the paddle method, JP14, using 900 mL of water as the test solution (37.0 ± 0.5 °C). The 
solubility of Compound-A in water was reported to be 1.72 g/L (20 °C) and therefore sink 
conditions could be achieved when 300 mg of Compound-A was used against 900 mL of water 
(more than 5 times of the solubility). The sampling points were 5, 10, 15, 30, 45, 60, 90 and 120 
min after the start of the test. 
Tablet dissolution: Three hundred milligrams film-coated tablets, made from M4 (H) or S4 (H), 
were tested by using a dissolution tester (NTR-VS3, Toyama Sangyo Co., Ltd., Osaka, Japan). 
At the given time points, 10 mL each of the dissolved solutions was taken, and 10 mL each of 
water, warmed at 37.0 ± 0.5 °C, was compensated immediately after the sampling. The sampled 
solutions were filtered through a membrane filter with a pore size of 0.45 µm (Millex-HV, 
Millipore Corporation, MA, USA). The first 4 mL of the filtrate was discarded, and subsequent 
filtrate was used as the sample solution. These solutions were analyzed by UV spectrometry at 
360 nm (UV-160, Shimadzu Corporation, Kyoto, Japan). 
Powder dissolution: Three hundred milligrams of M4 (H) or S4 (H) powder, sieved at a pore 
size of 1000 µm (JIS Z 8801, Tokyo Screen Co., Ltd., Tokyo, Japan), or 600 mg of the 1:1 
physical mixture with lactose (vortex-mixed for 5 min) was tested using a dissolution tester (DT-
610, Jasco Corporation, Tokyo, Japan) to investigate the wettability and dissolution behavior. At 
the given time points, each sample solution, passed through a 10-µm plastic filter (G3, Jasco 
Corporation, Tokyo, Japan), was automatically introduced into a UV/VIS spectrophotometer (V-
20 
520, Jasco Corporation, Tokyo, Japan) equipped with flow-through cells. These solutions were 
analyzed by UV spectrometry at 360 nm. 
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4. RESULTS AND DISCUSSION 
4.1 Flowability 
4.1.1 Characterization 
(1) Powder flow 
Flow properties of Compound-A powders are summarized in Table 2 and depicted in Figure 5. 
Overall, the poor powder flow of S-batches was obvious from the high values of angle of repose, 
compressibility, angle of spatula, and cohesion, and thus low flowability index. Comparing 
individual flow properties, angle of spatula represented the actual behavior of the powder flow of 
Compound-A appropriately, even better than flowability index. Therefore, angle of spatula was 
applied to quantify the powder flow in this study. The other three properties (angle of repose, 
compressibility & cohesion) were less sensitive especially to milled samples. 
All the intact S-batches were bulkier than intact M-batches and exhibited poorer powder flow. 
Hammer-milling of M4 made the material bulkier and the powder flow worse slightly, however, 
M4 (H) remained flowable practically. Hammer-milling of S4 had no impact on the powder flow 
and S4 (H) kept the worst flow. No remarkable effect on size reduction by hammer-milling may 
explain those results (see “Particle size distribution” & “Particle morphology” sections). 
Unexpectedly, jet-milled samples showed good performance on powder flow. Especially, S4 (J) 
had higher bulk density, lower compressibility and better powder flow than the intact and 
hammer-milled samples (S4 & S4(H)). In general, powerful micronization like jet-milling would 
reduce the particle size of materials to a few micron level. In fact, the mean particle size of M4 
(J) and S4 (J) was 4 µm (see “Particle size distribution” section). As the size reduction is 
accompanied by dramatic increase in the surface area, flowability of the material should become 
worse, theoretically. 
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Table 2 Flow properties of Compound-A powders. 
M4 M4 S4 S4
(H) (J) (H) (J)
Angle of repose 1 47.5 48.7 49.7 44.4 52.3 44.3 55.3 52.6 55.6 51.9 55.4 49.9
[ ° ] 2 49.4 47.3 47.6 46.9 50.4 46.6 57.0 56.4 55.0 54.1 53.6 48.6
3 47.7 49.6 48.4 44.5 52.3 44.4 55.0 55.6 53.6 53.9 54.4 53.6
Mean 48.2 48.5 48.6 45.3 51.7 45.1 55.8 54.9 54.7 53.3 54.5 50.7
SD 1.0 1.2 1.1 1.4 1.1 1.3 1.1 2.0 1.0 1.2 0.9 2.6
% RSD 2.2 2.4 2.2 3.1 2.1 2.9 1.9 3.7 1.9 2.3 1.7 5.1
Point b 12 12 12 15 12 15 9.5 10 10 12 10 12
Bulk density 1 0.308 0.262 0.257 0.331 0.187 0.116 0.138 0.180 0.178 0.132 0.136 0.151
[g/mL] a 2 0.297 0.258 0.256 0.327 0.190 0.111 0.149 0.179 0.175 0.125 0.137 0.157
3 0.309 0.262 0.262 0.319 0.185 0.115 0.148 0.183 0.181 0.127 0.138 0.153
Mean 0.305 0.261 0.258 0.326 0.187 0.114 0.145 0.181 0.178 0.128 0.137 0.154
SD 0.007 0.002 0.003 0.006 0.003 0.003 0.006 0.002 0.003 0.004 0.001 0.003
% RSD 2.2 0.9 1.2 1.9 1.3 2.3 4.2 1.2 1.7 2.8 0.7 2.0
Tapped density 1 0.448 0.434 0.435 0.482 0.414 0.243 0.362 0.423 0.447 0.331 0.343 0.313
[g/mL] a 2 0.444 0.427 0.429 0.477 0.418 0.237 0.371 0.431 0.450 0.321 0.343 0.317
3 0.446 0.429 0.432 0.475 0.416 0.240 0.368 0.428 0.451 0.331 0.346 0.307
Mean 0.446 0.430 0.432 0.478 0.416 0.240 0.367 0.427 0.449 0.328 0.344 0.312
SD 0.002 0.004 0.003 0.004 0.002 0.003 0.005 0.004 0.002 0.006 0.002 0.005
% RSD 0.4 0.8 0.7 0.8 0.5 1.2 1.2 0.9 0.5 1.8 0.5 1.6
Compressibility 1 31.3 39.6 40.9 31.3 54.8 52.3 61.9 57.4 60.2 60.1 60.3 51.8
[%] 2 33.1 39.6 40.3 31.4 54.5 53.2 59.8 58.5 61.1 61.1 60.1 50.5
3 30.7 38.9 39.4 32.8 55.5 52.1 59.8 57.2 59.9 61.6 60.1 50.2
Mean 31.7 39.4 40.2 31.9 55.0 52.5 60.5 57.7 60.4 60.9 60.2 50.8
SD 1.3 0.4 0.8 0.8 0.5 0.6 1.2 0.7 0.6 0.8 0.2 0.8
% RSD 4.0 1.0 2.0 2.6 0.9 1.1 2.0 1.1 1.1 1.3 0.3 1.7
Point b 9.5 2 2 9.5 0 0 0 0 0 0 0 0
Angle of spatula 1 55.3 58.8 60.5 57.5 65.1 58.2 79.0 80.6 78.4 78.1 79.7 60.5
[ ° ] 2 53.5 60.3 60.9 57.6 65.5 55.4 78.4 78.5 77.7 77.1 80.6 58.6
3 56.5 58.6 59.4 57.7 66.2 53.9 77.9 81.2 77.1 77.8 80.0 60.1
Mean 55.1 59.2 60.3 57.6 65.6 55.8 78.4 80.1 77.7 77.7 80.1 59.7
SD 1.5 0.9 0.8 0.1 0.6 2.2 0.6 1.4 0.7 0.5 0.5 1.0
% RSD 2.7 1.6 1.3 0.2 0.8 3.9 0.7 1.8 0.8 0.7 0.6 1.7
Point b 16 16 15 16 12 16 7 7 7 7 7 15
Cohesion 1 61.7 53.6 46.1 76.3 54.8 92.9 90.6 90.1 95.6 96.1 96.3 91.3
[%] 2 60.1 51.8 43.2 73.2 59.5 89.0 88.6 87.4 93.3 97.2 98.5 91.4
3 58.1 52.8 46.2 73.8 60.3 89.0 89.9 85.4 97.2 98.1 96.5 92.5
Mean 60.0 52.7 45.2 74.4 58.2 90.3 89.7 87.6 95.4 97.1 97.1 91.7
SD 1.8 0.9 1.7 1.6 3.0 2.3 1.0 2.4 2.0 1.0 1.2 0.7
% RSD 3.0 1.7 3.8 2.2 5.1 2.5 1.1 2.7 2.1 1.0 1.3 0.7
Point b 2 7 7 2 2 0 0 0 0 0 0 0
Flowability index b 39.5 37 36 42.5 26 31 16.5 17 17 19 17 27
c Poor Very Very Poor Very Very Very Very Very Very Very Very
Poor Poor Poor Poor very very very very very Poor
poor poor poor poor poor
M4 S1 S2 S3 S4Flow properties M1 M2 M3
 
a constant volume method (100 mL). 
b Carr's indices. 
c classification proposed by Carr (100 - 90 = excellent, 89 - 80 = good, 79 - 70 = fair, 69 - 60 = passable, 59 - 40 = 
poor, 39 - 20 = very poor, 19 - 0 = very, very poor). 
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Figure 5 Flow properties of Compound-A powders. 
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(2) Chemical purity 
Impurity profiles of Compound-A batches are summarized in Table 3, and the correlation with 
flowability is shown in Figure 6 together with the typical HPLC chromatograms. A small 
difference in the impurity profiles between M- and S- batches were found, however, the content 
of individual impurities was only 0.1 % in maximum. Furthermore, no correlation could be 
found between the total amount of related substances and angle of spatula, an indicator of 
flowability. 
HPLC analysis clarified that there was no correlation between the chemical purity and 
flowability. As expected neither hammer-milling nor jet-milling caused any change in the 
impurity profiles. 
Table 3 Impurity profiles of Compound-A batches. 
M4 M4 S4 S4
(H) (J) (H) (J)
0.56 0.05 % 0.03 % 0.03 % 0.03 % 0.04 % 0.04 % -- -- 0.02 % 0.03 % 0.03 % 0.04 %
0.95 0.03 % 0.04 % 0.03 % 0.01 % 0.01 % 0.01 % 0.03 % 0.03 % 0.05 % 0.04 % 0.04 % 0.04 %
0.96 -- -- -- -- -- -- -- -- 0.01 % -- -- --
0.99 0.01 % -- -- -- 0.01 % 0.01 % -- -- -- -- -- --
1.03 -- -- -- -- -- -- -- -- 0.01 % -- -- --
1.05 -- -- -- -- 0.01 % 0.02 % -- -- 0.03 % 0.02 % 0.02 % 0.03 %
1.06 -- -- -- -- -- -- -- -- -- -- 0.01 % --
1.11 -- 0.01 % 0.01 % -- 0.01 % -- -- -- -- -- -- --
1.16 -- -- -- -- -- -- -- -- -- 0.01 % 0.01 % 0.01 %
1.17 -- -- -- -- -- -- -- -- 0.02 % 0.01 % 0.01 % 0.01 %
1.18 -- -- -- -- -- -- -- -- 0.03 % 0.01 % 0.01 % 0.01 %
1.20 -- -- -- -- -- -- -- -- 0.01 % -- 0.01 % 0.01 %
1.24 0.02 % 0.02 % 0.02 % 0.02 % 0.02 % 0.02 % -- 0.02 % 0.03 % 0.01 % 0.01 % 0.02 %
1.26 -- -- -- -- -- -- -- -- 0.04 % -- -- --
1.28 -- -- -- -- -- -- -- -- 0.02 % -- -- --
1.30 -- -- -- -- -- -- 0.01 % 0.02 % 0.14 % 0.03 % 0.03 % 0.03 %
1.34 -- -- -- -- -- -- 0.04 % 0.10 % 0.02 % 0.10 % 0.10 % 0.10 %
1.45 -- -- -- -- -- -- -- -- 0.01 % 0.01 % -- --
1.46 -- -- -- -- -- -- -- -- 0.01 % 0.01 % 0.01 % 0.01 %
1.47 -- -- -- -- -- -- -- -- 0.01 % -- -- --
1.50 -- -- -- -- -- -- -- -- 0.01 % -- -- --
1.51 -- -- -- -- -- -- -- -- 0.01 % -- -- --
1.59 -- -- -- -- -- -- 0.02 % 0.02 % -- 0.02 % 0.02 % 0.02 %
Total 0.11 % 0.09 % 0.08 % 0.07 % 0.08 % 0.08 % 0.10 % 0.18 % 0.44 % 0.30 % 0.31 % 0.32 %
S4M4 S1 S2 S3RRT M1 M2 M3
 
RRT: relative retention time to the free base of Compound-A. (Mean, n=3) 
--: not detected (less than 0.01 %). 
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Figure 6 HPLC analysis of Compound-A batches. a) Typical chromatograms. b) Correlation between 
chemical purity & flowability. 
 
(3) Crystal form 
Typical XRPD patterns, DSC traces, and IR spectra of Compound-A batches are shown in 
Figure 7. 
Representative peaks in the XRPD patterns of Compound-A batches, mortar-ground (of intact), 
hammer-milled and jet-milled, are summarized in Table 4, Table 5 and Table 6, respectively. X-
ray diffraction peaks of M- and S-batches were detected at the same diffraction angles. The 
difference in the intensities observed in mortar-ground (of intact) and hammer-milled samples 
may reflect the different primary particle size (see “Particle morphology” section). In fact, 
diffraction patterns of M4 (J) and S4 (J), of which particle size was nearly equivalent, were very 
similar to each other, suggesting the same crystal form and crystallinity. 
DSC data of Compound-A batches are summarized in Table 7. The DSC traces showed a 
melting endothermic peak with the following relationships in the onset and peak temperatures; 
• Intact ≥ Hammer-milled > Jet-milled 
• M4 > S4, M4 (H) > S4 (H), M4 (J) > S4 (J) 
The former relationship can be explained by the difference in particle size 19, and the latter 
should be the result of melting-point depression caused by the impurity (M4 series: 0.07 – 
0.08 %; S4 series: 0.30 – 0.32 %). No consistent tendency could be found on the enthalpy (heat 
of fusion), where the relatively large variation may be the results of unstable DSC traces due to 
the decomposition of the salt, simultaneously occurred with melting. No peak other than melting 
could be detected at any batch. 
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Representative absorption peaks in the IR spectra of Compound-A batches are summarized in 
Table 8. All the batches exhibited similar intensities of absorption at the same wave numbers, 
suggesting the same crystal form and conformation. 
X-ray powder diffractometry, differential scanning calorimetry and infrared spectrophotometry 
demonstrated that there was no difference in the crystal form between M- and S-batches. 
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Figure 7 Crystal form of Compound-A batches. a) Typical XRPD patterns. b) Typical DSC traces. c) 
Typical IR spectra. 
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Table 4 Representative peaks in the XRPD patterns of Compound-A batches, mortar-ground (of intact). 
2-theta d
[ ° ] [Å] Mean SD % RSD Mean SD % RSD Mean SD % RSD Mean SD % RSD
3.3 26.70 3781 320 8.5 100 0 0.0 1217 11 0.9 100 0 0.0
6.7 13.26 1957 136 6.9 52 1 1.7 682 11 1.6 56 1 1.9
10.4 8.50 177 15 8.7 5 1 12.0 188 5 2.8 15 1 3.6
11.4 7.73 697 37 5.3 19 2 13.1 646 6 0.9 53 1 1.6
12.5 7.10 583 24 4.0 16 2 12.4 556 3 0.5 46 1 1.2
13.1 6.77 765 17 2.2 20 2 9.5 623 5 0.8 51 1 1.7
14.0 6.32 1093 27 2.5 29 3 10.5 912 18 1.9 75 1 1.4
15.6 5.69 338 21 6.1 9 1 14.0 230 7 3.0 19 1 3.7
16.4 5.39 184 -- -- 5 -- -- 134 -- -- 11 -- --
17.2 5.16 500 28 5.6 13 2 13.0 281 13 4.6 23 1 4.8
18.0 4.93 793 66 8.3 21 3 15.0 603 8 1.3 50 1 1.6
18.3 4.85 1184 33 2.8 32 3 11.0 817 11 1.4 67 0 0.6
18.6 4.76 1034 36 3.5 28 3 10.9 816 24 2.9 67 2 3.5
20.3 4.38 3234 204 6.3 86 3 3.1 1352 37 2.8 111 4 3.6
20.8 4.26 1325 44 3.4 35 4 11.1 1113 24 2.1 91 1 1.5
23.0 3.87 1258 35 2.8 32 3 9.2 982 36 3.6 81 4 4.5
23.3 3.82 1467 2 0.2 39 3 8.4 982 13 1.3 81 2 2.0
23.7 3.75 164 13 8.2 5 1 13.6 127 9 7.3 10 1 6.6
25.1 3.54 301 29 9.6 8 1 16.2 274 9 3.2 22 1 4.0
26.0 3.42 1131 36 3.2 30 3 9.3 672 31 4.5 55 3 5.0
27.4 3.25 1046 31 3.0 28 3 9.7 391 8 1.9 32 0 1.3
28.8 3.09 1898 27 1.4 50 4 8.4 1079 15 1.3 89 2 2.0
Peaks M4 (mortar-ground) S4 (mortar-ground)
Intensity [cps] a Relative intensity [%] b Intensity [cps] a Relative intensity [%] b
 
(n=3) 
a processed by Peak Search for Windows 3.1, version 3.0 (Rigaku Corporation, Tokyo, Japan), based on Savitzky-
Golay's method (smoothing), Sonnevelt-Visser's method (background subtraction) & Rachinger's method (Kα2 
elimination). 
b to the intensity at 2θ = 3.3 °. 
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Table 5 Representative peaks in the XRPD patterns of Compound-A batches, hammer-milled. 
2-theta d
[ ° ] [Å] Mean SD % RSD Mean SD % RSD Mean SD % RSD Mean SD % RSD
3.3 26.70 7218 131 1.8 100 0 0.0 2918 126 4.3 100 0 0.0
6.7 13.26 4095 177 4.3 57 1 2.5 1533 71 4.6 53 1 1.2
10.4 8.50 124 14 11.5 2 0 12.3 254 23 9.1 9 1 13.4
11.4 7.73 559 28 5.0 8 0 6.3 914 21 2.2 31 1 4.7
12.5 7.10 336 59 17.6 5 1 18.6 531 6 1.0 18 1 4.4
13.1 6.77 601 61 10.2 8 1 11.8 827 36 4.4 28 2 7.4
14.0 6.32 799 24 3.0 11 0 4.1 1031 8 0.7 35 1 3.7
15.6 5.69 350 20 5.7 5 0 5.6 379 19 5.1 13 1 8.7
16.4 5.39 221 54 24.3 3 1 23.8 216 21 9.8 7 1 8.5
17.2 5.16 630 34 5.4 9 1 6.5 550 27 4.9 19 1 6.9
18.0 4.93 959 24 2.5 13 1 4.0 885 23 2.6 30 1 1.8
18.3 4.85 1426 61 4.3 20 1 5.6 1206 23 1.9 41 1 2.8
18.6 4.76 920 119 12.9 13 2 14.2 1135 24 2.1 39 2 5.0
20.3 4.38 6851 286 4.2 95 4 3.8 2812 160 5.7 96 1 1.4
20.8 4.26 977 72 7.4 14 1 9.0 1592 11 0.7 55 3 5.0
23.0 3.87 1379 -- -- 19 -- -- 1412 17 1.2 48 2 3.2
23.3 3.82 1659 96 5.8 23 2 6.7 1484 38 2.6 51 2 3.6
23.7 3.75 107 -- -- 2 -- -- 125 17 13.2 4 1 16.9
25.1 3.54 322 -- -- 4 -- -- 304 14 4.6 10 1 8.9
26.0 3.42 1393 77 5.5 19 1 3.7 1171 28 2.4 40 1 3.0
27.4 3.25 1954 54 2.7 27 1 3.1 1003 79 7.9 34 1 4.1
28.8 3.09 2594 50 1.9 36 1 3.2 1780 72 4.1 61 0 0.6
Peaks M4 (H) S4 (H)
Intensity [cps] a Relative intensity [%] b Intensity [cps] a Relative intensity [%] b
 
(n=3) 
a processed by Peak Search for Windows 3.1, version 3.0 (Rigaku Corporation, Tokyo, Japan), based on Savitzky-
Golay's method (smoothing), Sonnevelt-Visser's method (background subtraction) & Rachinger's method (Kα2 
elimination). 
b to the intensity at 2θ = 3.3 °. 
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Table 6 Representative peaks in the XRPD patterns of Compound-A batches, jet-milled. 
2-theta d
[ ° ] [Å] Mean SD % RSD Mean SD % RSD Mean SD % RSD Mean SD % RSD
3.3 26.70 1244 17 1.4 100 0 0.0 1137 40 3.5 100 0 0.0
6.7 13.26 680 3 0.5 55 1 1.9 654 10 1.6 58 1 2.0
10.4 8.50 183 15 8.4 15 1 8.2 208 12 5.7 18 2 8.4
11.4 7.73 641 16 2.5 52 2 3.9 663 12 1.7 58 2 2.9
12.5 7.10 522 12 2.2 42 1 3.1 559 24 4.3 49 1 1.9
13.1 6.77 605 1 0.2 49 1 1.3 640 35 5.4 56 4 6.9
14.0 6.32 864 18 2.1 69 2 2.5 881 20 2.2 78 2 2.9
15.6 5.69 262 15 5.6 21 1 5.0 265 16 6.1 23 2 8.8
16.4 5.39 185 3 1.7 15 0 2.6 179 16 8.7 16 2 10.7
17.2 5.16 292 21 7.3 23 2 6.8 304 13 4.3 27 0 0.8
18.0 4.93 672 23 3.4 54 1 2.7 672 24 3.5 59 1 1.4
18.3 4.85 773 10 1.3 62 1 2.0 840 23 2.8 74 1 1.2
18.6 4.76 723 27 3.7 58 2 4.2 834 18 2.2 73 4 4.9
20.3 4.38 1256 48 3.8 101 5 5.1 1350 49 3.6 119 7 5.6
20.8 4.26 1098 19 1.7 88 3 3.1 1136 54 4.8 100 3 2.9
23.0 3.87 996 27 2.7 80 2 2.2 1049 30 2.8 92 2 2.2
23.3 3.82 902 21 2.3 73 2 3.3 910 52 5.7 80 3 3.7
23.7 3.75 147 8 5.2 12 0 4.1 140 10 7.1 12 1 4.3
25.1 3.54 286 17 5.9 23 1 5.4 292 26 8.9 26 3 10.5
26.0 3.42 632 19 3.0 51 1 1.9 688 19 2.8 61 2 3.6
27.4 3.25 331 6 1.7 27 0 0.3 369 45 12.2 32 4 12.3
28.8 3.09 983 15 1.5 79 1 1.6 1017 35 3.4 90 6 7.1
Intensity [cps] a Relative intensity [%] b Intensity [cps] a Relative intensity [%] b
Peaks M4 (J) S4 (J)
 
(n=3) 
a processed by Peak Search for Windows 3.1, version 3.0 (Rigaku Corporation, Tokyo, Japan), based on Savitzky-
Golay's method (smoothing), Sonnevelt-Visser's method (background subtraction) & Rachinger's method (Kα2 
elimination). 
b to the intensity at 2θ = 3.3 °. 
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Table 7 DSC data of Compound-A batches. 
M4 M4 S4 S4
(H) (J) (H) (J)
Melting temperature Onset 1 213.1 212.7 211.5 211.4 211.5 210.8
[°C] 2 212.8 212.5 211.4 211.3 211.5 210.8
3 213.0 212.7 211.5 211.7 211.3 210.5
Mean 213.0 212.6 211.5 211.5 211.4 210.7
SD 0.2 0.1 0.1 0.2 0.1 0.2
% RSD 0.1 0.1 0.0 0.1 0.1 0.1
Peak 1 214.8 214.1 213.2 213.1 213.1 212.6
2 214.7 214.0 213.0 213.4 213.1 212.3
3 214.6 214.2 213.1 213.3 213.1 212.4
Mean 214.7 214.1 213.1 213.3 213.1 212.4
SD 0.1 0.1 0.1 0.2 0.0 0.2
% RSD 0.0 0.0 0.0 0.1 0.0 0.1
Heat of fusion 1 73.5 74.7 73.9 74.1 73.7 72.8
[J/g] 2 75.7 71.9 74.9 75.2 74.5 70.5
3 75.7 73.2 75.5 72.5 75.0 75.1
Mean 75.0 73.3 74.8 73.9 74.4 72.8
SD 1.3 1.4 0.8 1.4 0.7 2.3
% RSD 1.7 1.9 1.1 1.8 0.9 3.2
M4 S4
 
 
Table 8 Representative absorption peaks in the IR spectra of Compound-A batches. 
M4 M4 S4 S4
(H) (J) (H) (J)
3349 3342 3333 3342 3335 3343
2594 2594 2593 2593 2593 2594
1929 1929 1928 -- 1932 1946
3025 3024 3024 3024 3024 3024
2934 2934 2934 2933 2934 2933
1702 1701 1701 1700 1701 1701
1645 1645 1645 1645 1645 1645
1592 1592 1592 1592 1592 1592
1277 1277 1277 1277 1277 1277
799 799 799 799 799 799
746 746 746 746 746 746
699 699 699 699 699 699
636 636 636 636 636 636
C-O stretching (ether & acid)
C-H bending (aromatic rings)
C=O stretching (amide)
(acid)
C=C stretching (aromatic double bonds)
Wave number [cm-1]
O-H stretching (acid)
C-H stretching (aromatic rings)
(aliphatic hydrocarbons)
M4 S4
Assignment
 
--: not detected, due to the broad peak shape. (Mean, n=3) 
 
(4) Surface charge 
Zeta potential of Compound-A particles is summarized in Table 9, and depicted in Figure 8 
together with the typical power spectra. Zeta potential measurement indicated that there was no 
significant difference in the surface charge between M- and S-batches, where the surface of 
Compound-A particles was positively charged at approximately 20 mV. 
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Table 9 Surface charge of Compound-A particles. 
Zeta potential
Electrical field free Under electrical field Shift [mV]
M4 (J) 1 260.2 270.3 10.1 22.3
2 260.1 271.8 11.6 25.6
3 260.6 269.7 9.1 20.0
Mean 260.3 270.6 10.3 22.6
SD 0.2 1.1 1.3 2.8
% RSD 0.1 0.4 12.4 12.4
S4 (J) 1 261.3 268.6 7.3 16.1
2 260.4 268.7 8.2 18.2
3 260.2 269.6 9.3 20.6
Mean 260.6 268.9 8.3 18.3
SD 0.5 0.5 1.0 2.2
% RSD 0.2 0.2 12.3 12.3
Frequency [Hz]
 
 
a) Power spectra b) Zeta potential
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Figure 8 Zeta potential measurement of Compound-A particles. a) Typical power spectra. b) Zeta potential. 
 
(5) Particle size distribution 
Particle size of Compound-A batches, measured after 3-minutes’ sonication in the medium 
(0.45-µm filtrate of Compound-A saturated n-hexane), is summarized in Table 10, and the 
typical particle size distribution patterns are shown in Figure 9. A difference in particle size was 
found on laser diffractometry. The mean particle size of typical M- and S-batches was 25 µm 
and 7 µm, respectively (intact & hammer-milled). The smaller particle size and therefore the 
larger surface area of S-batches could be a reason for the poor flowability. However, this 
assumption was contradictory to the better flowability of jet-milled samples, of which mean 
particle size was 4 µm, as discussed in the “Powder flow” section. 
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Table 10 Particle size of Compound-A batches, measured after 3-minutes’ sonication in the medium 
(0.45-µm filtrate of Compound-A saturated n-hexane). 
M4 M4 S4 S4
(H) (J) (H) (J)
Mean diameter 1 23.1 23.1 4.6 7.0 7.1 3.7
[µm] 2 25.0 23.5 4.4 7.2 7.1 3.5
3 25.9 23.3 4.5 7.1 7.2 4.0
Mean 24.7 23.3 4.5 7.1 7.1 3.7
SD 1.4 0.2 0.1 0.1 0.0 0.3
% RSD 5.7 0.9 2.3 1.4 0.6 7.1
Median diameter d10 1 9.1 9.4 2.8 3.6 3.6 2.3
[µm] 2 9.7 9.0 2.6 3.7 3.6 2.2
3 9.7 8.9 2.7 3.6 3.8 2.4
Mean 9.5 9.1 2.7 3.6 3.6 2.3
SD 0.4 0.2 0.1 0.1 0.1 0.1
% RSD 3.7 2.6 4.7 2.3 2.9 4.8
d50 1 20.3 20.2 4.4 6.3 6.3 3.5
2 22.0 20.7 4.2 6.5 6.3 3.4
3 22.0 20.5 4.3 6.3 6.4 3.8
Mean 21.4 20.5 4.3 6.3 6.3 3.6
SD 1.0 0.3 0.1 0.1 0.1 0.2
% RSD 4.6 1.3 2.4 1.7 1.0 6.8
d90 1 40.8 40.7 6.7 11.5 11.6 5.3
2 44.3 41.5 6.5 11.8 11.6 5.0
3 47.4 41.3 6.5 11.7 11.6 5.9
Mean 44.2 41.2 6.6 11.7 11.6 5.4
SD 3.3 0.4 0.1 0.1 0.0 0.5
% RSD 7.4 1.0 1.3 1.1 0.4 8.4
M4 S4
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Figure 9 Typical particle size distribution patterns of Compound-A batches, measured after 3-
minutes’ sonication in the medium (0.45-µm filtrate of Compound-A saturated n-hexane). 
Values in each figure indicate the mean volume diameter (Mean, n=3). 
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(6) Particle morphology 
Microscopic observation revealed that there was a significant difference in particle shape 
between M- and S-batches. Scanning electron micrographs of Compound-A particles are shown 
in Figure 10. Primary particles of M-batches were plate-shaped, while those of S-batches were 
mostly elongated (intact and hammer-milled). The jet-milled samples were composed of small 
plate-shaped particles. The particle surface of all the batches appeared to be smooth and no 
significant difference could be found in the surface roughness. 
Intact Hammer-milled Jet-milled
M4 M4 (H) M4 (J)
S4 (J)S4 (H)S4
        20 µm
        20 µm
        20 µm
        20 µm
        20 µm
        20 µm        4 µm         4 µm         4 µm
        4 µm
 
Figure 10 Scanning electron micrographs of Compound-A particles. Magnification: 500 x & 5000 x. 
 
Image analysis proved the morphological difference. Dimensions of Compound-A primary 
particles, derived from image analysis, are summarized in Table 11, and the shape factors are 
depicted in Figure 11. The mean particle sizes determined as circle equivalent diameter, length 
and width could be classified into three groups. These values were well consistent with the mean 
diameters measured by laser diffractometry when recalculated as mean number diameter (data 
not shown). Size reduction effect of jet-milling was remarkable, but that of hammer-milling was 
not. 
• Size: M4, M4 (H) >> S4, S4 (H) >> M4 (J), S4 (J) 
The shape factors determined as circularity and elongation ratio could be classified into two 
groups. It was demonstrated that S-batches were less circular and more elongated than M-
batches (intact and hammer-milled). It was also found that the variation in shape of S4 and S4 
(H) was wider than the other batches as presented in relative standard deviations of circularity 
and elongation ratio. Jet-milling dissolved all those differences. 
• Circularity: M4, M4 (H), M4 (J), S4 (J) >> S4, S4 (J) 
• Elongation ratio: M4, M4 (H), M4 (J), S4 (J) << S4, S4 (J) 
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Table 11 Dimensions of Compound-A primary particles. 
M4 M4 S4 S4
(H) (J) (H) (J)
Circle CL-lower 11.52 11.01 2.15 4.64 4.25 2.21
equivalent Mean 11.84 11.33 2.22 4.76 4.36 2.28
diameter CL-upper 12.16 11.64 2.28 4.88 4.46 2.34
[µm] SD 5.50 5.27 1.08 2.14 1.84 1.15
% RSD 46.48 46.50 48.69 44.95 42.21 50.57
Circularity CL-lower 0.70 0.68 0.73 0.59 0.57 0.71
Mean 0.71 0.69 0.73 0.60 0.57 0.72
CL-upper 0.71 0.69 0.74 0.61 0.58 0.72
SD 0.09 0.11 0.08 0.13 0.15 0.09
% RSD 12.32 15.58 11.52 22.10 25.36 12.79
Length CL-lower 15.42 15.08 2.87 7.32 6.88 3.01
[µm] Mean 15.85 15.51 2.95 7.52 7.05 3.10
CL-upper 16.28 15.93 3.04 7.71 7.22 3.20
SD 7.42 7.06 1.47 3.46 3.01 1.61
% RSD 46.83 45.51 49.76 46.05 42.65 51.82
Width CL-lower 10.74 10.06 1.96 3.61 3.29 1.96
[µm] Mean 11.06 10.39 2.03 3.72 3.39 2.02
CL-upper 11.39 10.71 2.09 3.83 3.49 2.08
SD 5.60 5.40 1.05 1.96 1.74 1.07
% RSD 50.65 52.03 52.04 52.88 51.40 52.76
Elongation CL-lower 1.48 1.58 1.48 2.17 2.27 1.57
ratio Mean 1.51 1.62 1.50 2.22 2.32 1.59
CL-upper 1.53 1.65 1.53 2.27 2.38 1.62
SD 0.44 0.59 0.38 0.87 0.98 0.44
% RSD 28.96 36.49 25.34 39.31 42.36 27.80
N 1151 1076 1091 1217 1231 1135
Shape descriptors M4 S4
 
CL: 95 % confidence limit. 
N: number of primary particles counted. 
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Figure 11 Shape of Compound-A primary particles. 
 
The difference in particle shape was consistent with the difference in flowability; All the batches 
composed of plate-shaped particles showed good powder flow, whereas those composed of 
needle-shaped particles showed poor flow. On the other hand, no reasonable explanation was 
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possible from all the other physicochemical properties tested in this study. It was assumed that 
particle shape was the critical factor determining the powder flow of Compound-A. 
The literature opinion of the impact of particle shape on the flowability seems to be in agreement 
1, 3,  9, 20, 21, 22; Elongated or irregular shaped particles showed high inter-particulate interactions i.e. 
high frictional and cohesive forces which inhibited powder flow. Recent literature pointed out 
that irregular shaped particles tended to accumulate triboelectricity at the corners of the particles 
and thus showed high adhesive forces between particles 21. High surface/volume ratio due to the 
irregularity was another reason 22. 
Some points should be considered before relying on the assumption that particle shape would 
determine the powder flow of Compound-A; 
• Not all the S-batch particles were perfect needles; Mostly elongated, but plate-shaped 
particles like M-batch’s also existed. 
• There was some doubt whether or not it was appropriate to deal with jet-milled samples on 
the same basis. If considered only within intact samples, the influence of particle shape alone 
on the powder flow was not fairly evaluated because the particle size was not in the same 
level. 
• Different crystallizers employed in Company-M and –S could cause significantly different 
particle densification, which may affect the powder flow. 
Therefore, there was a need to prepare some particles having completely different shape 
(elongation ratio) but comparable size by using the same set-up. 
4.1.2 Modification of crystal habit 
Recrystallization is the final process of drug substance manufacturing, and crystal habit, namely 
particle shape and size, is then determined. Recrystallization studies were started with a 
minimum batch size of 1.5 g to investigate which process variables should be taken into account 
to obtain desired crystal habit. Batch information on the recrystallization process (batch size: 1.5 
g) is summarized in Table 12. The yield of each batch was dependent on the crystallizing solvent 
and the temperature at recovery, and was considered reasonable. 
Optical micrographs of recrystallized Compound-A particles (batch size:1.5 g) are shown in 
Figure 12. As long as the cooling rate was rapid (ice water bath), all the solvents brought small 
plate-shaped particles, which formed firm agglomerates (R3: 50 % methanol; R5: ethanol; R8: 
methanol). The bulk density of these batches was very similar to each other (Table 13), 
suggesting similar flowability. In fact, those batches exhibited good powder flow although only 
qualitative evaluation was possible due to the small quantity. Natural cooling (room temperature) 
brought relatively large particles (R4) when compared to rapid cooling (R8). Plate-shaped seeds 
brought slightly elongated particles, which formed agglomerates only in part and exhibited 
relatively low bulk density and poor powder flow (R6). Needle-shaped seeds brought needle-
shaped particles with no firm agglomerates, which showed very low bulk density and very poor 
powder flow (R7). 
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Table 12 Batch information on the recrystallization process of Compound-A (batch size: 1.5 g). 
Time
[min] R3 R5 R8 R4 R6 R7
-20 -- 24.3 -- -- -- --
-18 24.4 27.7 22.9 -- -- --
-16 27.0 35.5 25.8 25.4 24.2 22.5
-14 34.2 43.3 33.1 28.6 27.6 26.3
-12 40.8 50.5 40.7 35.2 35.2 34.3
-10 47.9 57.3 47.3 42.5 43.0 42.4
-8 54.5 63.7 53.8 48.9 50.2 49.6
-6 60.7 69.2 59.8 55.1 56.8 56.2
-4 66.8 73.8 62.5 60.8 62.2 61.7
-2 67.5 75.6 62.6 63.0 62.8 62.2
0 (start of cooling) 66.2 75.5 62.6 63.3 62.8 62.2
2 43.0 41.4 31.8 57.8 56.8 57.3
4 23.4 17.0 15.7 52.8 52.0 52.2
6 13.5 9.2 10.0 48.6 47.9 48.1
8 9.2 5.8 6.8 45.0 44.6 44.8
10 6.0 4.2 5.0 42.2 41.6 41.7
12 3.8 2.8 4.1 39.7 37.5 39.0
14 2.8 1.9 2.7 37.4 35.6 37.0
16 2.4 1.5 2.1 35.6 34.3 35.3
18 2.1 1.3 1.9 34.1 33.0 34.0
20 2.0 1.3 1.8 32.8 31.9 32.6
22 1.8 1.3 1.8 31.6 30.8 31.5
24 1.7 1.3 1.7 30.7 30.1 30.6
26 1.6 1.3 1.7 30.0 29.4 29.9
28 1.5 1.3 1.5 29.2 28.9 29.1
30 1.5 1.3 1.5 28.8 28.3 28.7
32 -- -- -- 28.3 -- --
34 -- -- -- 28.0 -- --
36 -- -- -- 27.8 -- --
38 -- -- -- 27.3 -- --
40 -- -- -- 27.0 -- --
42 -- -- -- 26.8 -- --
44 -- -- -- 26.5 -- --
46 -- -- -- 26.2 -- --
48 -- -- -- 26.0 -- --
50 -- -- -- 26.0 -- --
60 1.7 1.3 1.5 25.3 24.8 24.9
90 1.9 1.5 1.5 24.3 23.8 24.1
120 1.5 1.9 1.6 24.0 23.4 23.8
Solvent 50 % Methanol Ethanol Methanol Methanol Methanol Methanol
Cooling Rapid Rapid Rapid Natural Natural Natural
Seeding -- -- -- -- Plates Needles
Washing -- -- -- -- -- --
Yield [%] 90.4 90.0 79.9 68.9 71.3 71.5
--: not applicable. : transparent : seeding
Temperature [°C]
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        20 µm
        20 µm
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        100 µm        20 µm
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        100 µm        20 µm
 
Figure 12 Optical micrographs of recrystallized Compound-A particles (batch size: 1.5 g). 
Magnification: 100 x & 500 x. R3: rapid cooling (50 % methanol). R5: rapid cooling (ethanol). 
R8: rapid cooling (methanol). R4: natural cooling (methanol). R6: natural cooling (methanol) + 
plate-seeding. R7: natural cooling (methanol) + needle-seeding. 
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Table 13 Flow properties of recrystallized Compound-A powders (batch size: 1.5 g). 
Bulk density
[g/mL] a
R7
0.344 0.151 0.2420.254 0.252 0.199 0.177 0.145
R3 R5 R4 R6M4 S4 R8
 
a constant mass method (1 g in 10-mL graduated glass cylinder, readable to 0.1 mL). 
 
Confirmatory recrystallization studies were performed with a batch size of 15 g to investigate the 
relationship between particle shape and flowability thoroughly. Referring to the findings at the 
minimum batch size, the following 4 batches were prepared; 
• R10: Rapid cooling (Small plates were expected.) 
• R11: Natural cooling + needle-seeding (Mid-sized needles were expected.) 
• R12: Rapid cooling + n-hexane washing (Small plates having no agglomerates were 
expected.) 
• R13: Slow cooling (Large plates were expected.) 
Methanol was selected as the crystallizing solvent since it was a standard solvent being 
employed for the actual drug substance manufacturing. Batch information on the 
recrystallization process (batch size: 15 g) is summarized in Table 14 and depicted in Figure 13. 
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Table 14 Batch information on the recrystallization process of Compound-A (batch size: 15 g). 
--: not applicable. : transparent : seeding
--
--
68.6
R11
21.7
19.7
Methanol
Slow
35.1
31.7
27.1
24.3
--
--
43.4
41.0
--
--
46.4
--
--
50.3
--
--
55.2
--
--
--
--
--
--
--
64.1
63.5
62.4
61.1
64.2
64.4
64.4
64.2
40.3
46.5
53.2
59.4
22.1
23.2
27.5
33.529.2
24.0
22.6
--
57.2
50.5
43.8
36.5
51.2
64.2
64.0
63.8
11.8
14.9
21.2
33.5
6.4
7.4
8.4
10.0
2.5
3.1
3.9
5.1
1.7
1.8
2.0
2.2
--
--
--
1.7
1.5
--
--
--
--
--
1.5
1.5
Rapid
Methanol
--
--
Needles
--
63.6 78.5
n-Hexane
--
--
--
Methanol
Natural
26.3
24.3
--
--
34.3
33.8
--
30.5
37.0
36.1
35.5
35.0
39.9
39.5
38.5
37.8
44.8
43.5
42.3
41.3
50.7
49.0
47.5
46.0
58.8
56.5
54.5
52.5
60.2
64.2
64.4
61.7
33.2
40.6
47.1
54.4
--
21.3
22.6
27.028.7
23.2
21.5
--
57.4
50.8
43.7
36.1
55.0
64.7
64.7
63.5
14.2
17.9
23.5
33.2
5.6
7.8
9.2
11.1
2.0
2.3
3.0
3.8
1.6
1.8
1.8
2.0
--
--
--
1.5
1.4
--
--
--
--
--
1.4
1.6
Rapid
Methanol
--
--
Seeding
Washing
Yield [%] 75.5
--
--
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Figure 13 Recrystallization process of Compound-A batches (batch size: 15 g). Crystallizing solvent: 
methanol. Time zero means the start of cooling. 
 
Optical micrographs of recrystallized Compound-A particles (batch size: 15 g) are shown in 
Figure 14. Dimensions of the primary particles, derived from image analysis, are summarized in 
Table 15 and the elongation ratio is depicted in Figure 15. Primary particles of batches 
recrystallized under rapid cooling were small plates (R10 & R12). Almost all of the particles 
formed firm agglomerates of which apparent particle size was around 100 µm. Slow cooling 
brought large plates (R13). These particles formed similar agglomerates to R10 and R12, 
however, the degree of agglomeration appeared to be low; A large number of free primary 
particles were seen. Perfect needles were produced by needle-seeding (R11). The length of the 
primary particles of R11 was comparable to that of R13, and the width was comparable to that of 
R10 and R12. Some agglomerates were also seen, however, they were considered not so dense 
since light transmission was good on the picture. The elongation ratio of plate-shaped batches, 
R10, R12 and R13, was around 1.5 like M-batches, while that of needle-shaped R11 was 3.3. 
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R10 R11
R12 R13
        100 µm
        100 µm
        100 µm
        100 µm
        20 µm         20 µm
        20 µm         20 µm
 
Figure 14 Optical micrographs of recrystallized Compound-A particles (batch size: 15 g). 
Magnification: 100 x & 500 x. R10: rapid cooling. R11: natural cooling + needle-seeding. R12: 
rapid cooling + n-hexane washing. R13: slow cooling. Crystallizing solvent: methanol. 
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Table 15 Dimensions of recrystallized Compound-A primary particles (batch size: 15 g). 
Circle CL-lower 3.15 5.62 3.38 8.68
equivalent Mean 3.21 5.76 3.47 8.99
diameter CL-upper 3.28 5.90 3.55 9.29
[µm] SD 1.08 2.31 1.32 4.96
% RSD 33.67 40.06 38.15 55.14
Circularity CL-lower 0.82 0.50 0.82 0.75
Mean 0.83 0.51 0.83 0.75
CL-upper 0.83 0.52 0.83 0.76
SD 0.07 0.16 0.07 0.10
% RSD 8.77 30.71 8.31 12.72
Length CL-lower 4.08 10.75 4.36 11.82
[µm] Mean 4.17 11.06 4.47 12.23
CL-upper 4.25 11.36 4.58 12.64
SD 1.52 4.89 1.76 6.59
% RSD 36.40 44.19 39.30 53.85
Width CL-lower 2.93 3.65 3.18 8.05
[µm] Mean 2.99 3.78 3.26 8.37
CL-upper 3.05 3.91 3.34 8.69
SD 0.99 2.11 1.29 5.22
% RSD 33.20 55.77 39.51 62.40
Elongation CL-lower 1.39 3.25 1.37 1.54
ratio Mean 1.41 3.35 1.39 1.57
CL-upper 1.42 3.44 1.40 1.61
SD 0.28 1.57 0.27 0.55
% RSD 19.61 46.89 19.69 35.05
N 1142 1002 1008 1003
R13Shape descriptors R10 R11 R12
 
CL: 95 % confidence limit. 
N: number of primary particles counted. 
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Figure 15 Shape of recrystallized Compound-A primary particles (batch size: 15 g). R10: rapid cooling. 
R11: natural cooling + needle-seeding. R12: rapid cooling + n-hexane washing. R13: slow 
cooling. Crystallizing solvent: methanol. 
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Particle size of recrystallized Compound-A batches (batch size: 15 g) determined by laser 
diffractometry is summarized in Table 16 (measured after 3-minutes’ sonication in the medium) 
and Table 17 (measured periodically under continuous stirring in the medium). De-
agglomeration behavior observed in the latter conditions is summarized in Table 18. The typical 
particle size distribution patterns are shown in Figure 16. In the case primary particles were 
plate-shaped (R10, R12 & R13), two peaks derived from primary particles and the agglomerates 
were detected together. A difference in the degree of agglomeration was found depending on the 
primary particle size. Almost all of R10 and R12 particles, which consisted of small plates, 
existed as agglomerates at 1-minute stirring, while only about a half R13 particles, which 
consisted of large plates, existed as agglomerates. On the other hand, no agglomerates derived 
peak was detected in the case of R11, composed of needles. It was found that the agglomerates 
of R11 observed by microscopy were extremely fragile. 
Table 16 Particle size of recrystallized Compound-A batches (batch size: 15 g), measured after 3-
minutes’ sonication in the medium (0.45-µm filtrate of Compound-A saturated n-hexane). 
Mean diameter 1 16.2 13.1 9.0 22.1
[µm] 2 16.7 13.1 9.0 23.9
3 16.3 13.7 8.6 21.6
Mean 16.4 13.3 8.8 22.5
SD 0.3 0.3 0.2 1.2
% RSD 1.7 2.4 2.3 5.4
Median diameter d10 1 4.6 5.2 4.4 9.2
[µm] 2 4.9 5.2 4.5 9.2
3 4.7 5.4 4.3 9.0
Mean 4.7 5.3 4.4 9.1
SD 0.1 0.1 0.1 0.1
% RSD 3.1 1.8 2.1 0.9
d50 1 13.8 11.7 8.3 19.3
2 15.2 11.6 8.4 19.2
3 14.4 12.0 7.9 19.0
Mean 14.5 11.7 8.2 19.2
SD 0.7 0.2 0.2 0.2
% RSD 5.0 1.8 2.9 1.0
d90 1 31.1 22.5 14.3 37.8
2 30.3 23.0 14.2 39.5
3 30.3 23.7 13.8 37.0
Mean 30.6 23.1 14.1 38.1
SD 0.4 0.6 0.3 1.3
% RSD 1.4 2.6 1.9 3.3
R10 R11 R12 R13
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Table 17 Particle size of recrystallized Compound-A batches (batch size: 15 g), measured 
periodically under continuous stirring in the medium (0.45-µm filtrate of Compound-A 
saturated n-hexane). 
Time
[min]
Mean diameter 1 79.6 16.4 76.3 71.0
[µm] 2 77.6 16.0 69.3 69.2
5 74.9 15.4 50.2 62.2
10 68.2 15.2 31.4 55.7
30 54.1 15.8 13.2 47.5
60 48.0 16.1 9.9 42.0
Median diameter d10 1 40.9 5.1 21.6 12.7
[µm] 2 38.8 5.2 11.1 12.6
5 35.6 5.2 5.6 11.9
10 20.2 5.3 4.5 11.2
30 6.4 5.7 4.4 10.7
60 5.5 5.8 4.5 10.1
d50 1 82.8 12.2 82.1 66.3
2 81.8 12.2 76.4 64.0
5 77.6 12.4 58.7 54.8
10 74.4 12.6 12.9 46.0
30 61.4 13.6 9.0 36.5
60 53.2 13.7 8.8 30.6
d90 1 107.9 29.3 111.8 135.7
2 104.3 28.7 105.4 132.7
5 105.9 27.7 92.1 121.2
10 99.7 27.3 76.6 110.6
30 92.9 28.3 22.3 97.8
60 90.9 28.5 16.2 88.6
R10 R11 R12 R13
 
 
Table 18 De-agglomeration behavior of recrystallized Compound-A batches (batch size: 15 g), 
measured periodically under continuous stirring in the medium (0.45-µm filtrate of 
Compound-A saturated n-hexane). 
Time
Size Volume Size Volume Size Volume Size Volume
[min] [µm] a [%] [µm] a [%] [µm] a [%] [µm] a [%]
Primary 1 -- -- 12.2 99.7 9.5 9.3 -- --
particles 2 -- -- 12.2 99.6 8.5 14.6 -- --
5 -- -- 12.3 99.7 7.8 36.1 -- --
10 -- -- 12.6 99.7 7.8 60.4 -- --
30 7.6 25.8 13.6 100.0 9.0 100.0 18.7 56.5
60 8.0 36.4 13.6 99.7 8.8 100.0 17.7 60.0
Secondary 1 82.9 99.6 -- -- 84.9 90.7 96.0 58.8
agglomerates 2 85.1 86.2 -- -- 80.8 85.4 94.2 58.9
5 77.7 99.6 -- -- 72.9 63.9 89.7 54.6
10 76.8 89.9 -- -- 65.4 39.6 85.4 50.0
30 70.9 74.2 -- -- -- -- 78.9 43.5
60 70.5 63.6 -- -- -- -- 72.1 40.0
R10 R11 R12 R13
 
a median diameter. 
--: no discriminable peak. 
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Figure 16 Typical particle size distribution patterns of recrystallized Compound-A batches (batch 
size: 15 g). Medium: 0.45-µm filtrate of Compound-A saturated n-hexane. “Stirred”: measured 
periodically under continuous stirring in the medium (no pretreatment). “Sonicated”: measured 
after 3-minutes’ sonication in the medium. Values in each figure indicate the mean volume 
diameter after 3-minutes’ sonication (Mean, n=3). R10: rapid cooling. R11: natural cooling + 
needle-seeding. R12: rapid cooling + n-hexane washing. R13: slow cooling. Crystallizing 
solvent: methanol. 
 
Flow properties of recrystallized Compound-A batches (batch size: 15 g) are summarized in 
Table 19 and depicted in Figure 17. The bulk density and the angle of spatula were clearly 
dependent on the primary particle shape and size. Small plates (R10 & R12) showed high bulk 
density and low angle of spatula, while needles (R11) showed low bulk density and high angle of 
spatula, like the values of S-batches. Large plates (R13) showed intermediate position in both 
properties. 
Table 19 Flow properties of recrystallized Compound-A batches (batch size: 15 g). 
Bulk density 1 0.331 0.132 0.255 0.108 0.238 0.167
[g/mL] a 2 0.327 0.125 0.258 0.110 0.238 0.170
3 0.319 0.127 0.256 0.110 0.239 0.167
Mean 0.326 0.128 0.256 0.109 0.238 0.168
SD 0.006 0.004 0.002 0.002 0.001 0.002
% RSD 1.9 2.8 0.7 1.4 0.4 0.9
Angle of spatula 1 57.5 78.1 49.9 74.9 54.6 57.7
[ ° ] 2 57.6 77.1 48.0 77.2 51.5 60.1
3 57.7 77.8 48.0 79.0 54.7 59.2
Mean 57.6 77.7 48.6 77.0 53.6 59.0
SD 0.1 0.5 1.1 2.1 1.8 1.2
% RSD 0.2 0.7 2.3 2.7 3.4 2.1
R11 R12 R13M4 S4 R10
 
a constant volume method (30 mL). 
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Figure 17 Flow properties of recrystallized Compound-A powders (batch size: 15 g). R10: rapid 
cooling. R11: natural cooling + needle-seeding. R12: rapid cooling + n-hexane washing. R13: 
slow cooling. Crystallizing solvent: methanol. 
 
Influence of process variables during recrystallization of Compound-A is summarized in Table 
20. 
• Crystallizing solvent: Methanol, 50 % methanol or ethanol was used as the crystallizing 
solvent. As long as the cooling rate was rapid (ice water bath), all the solvents brought small 
plate-shaped particles, which formed firm agglomerates and exhibited good powder flow. 
Crystallizing solvent hardly affected the particle morphology and flowability. 
• Cooling rate: Rapid cooling, natural cooling (room temperature) and slow cooling (warm 
water bath) were compared using methanol as the crystallizing solvent. All the cooling rates 
brought plate-shaped particles. Faster cooling resulted in smaller primary particles, higher 
degree of agglomeration, and better powder flow. Cooling rate was an important variable 
relating to the primary particle size and flowability. 
• Seeding: 10 % equivalent of seeds was added before spontaneous nucleation during the 
cooling process (natural cooling) using methanol as the crystallizing solvent. Plate-shaped 
seeds brought slightly elongated particles, which formed agglomerates only in part and 
exhibited poor powder flow. Needle-shaped seeds brought perfect needles with no firm 
agglomerates, which showed extremely poor powder flow. Seeding induced nucleation and 
crystal growth at lower degree of the solute saturation, which would be favorable for the 
elongation of Compound-A crystals. Complete dissolution of starting material before cooling 
has to be assured to avoid producing elongated particles, which would exhibit poor powder 
flow. 
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• Washing with anti-solvent: Precipitate recovered on the filter was washed with n-hexane 
before the drying process (crystallizing solvent: methanol; cooling rate: rapid). This 
additional processing should realize complete de-agglomeration before drying and also was 
expected to prevent aggregation and agglomeration during drying. However, this attempt had 
only slight effect; Most of the particles formed agglomerates again after drying. This 
agglomeration behavior was considered as an essential nature for plate-shaped particles of 
Compound-A. 
Table 20 Influence of process variables during recrystallization of Compound-A. 
Process Options
variables Degree of Powder
Size Shape agglomeration flow
Crystallizing Methanol
solvent a 50 % Methanol N/S (small) N/S (plates) N/S (high) N/S (excellent)
Ethanol
Cooling Rapid Small High Excellent
rate b Natural N/S (plates)
Slow Large Moderate Good
Seeding c None Small Plates High Excellent
Plate-shaped
Needle-shaped Large Needles Low Poor
Washing with None High Excellent
anti-solvent d n-Hexane Moderate Good
Crystal habit
Impact on particle morphology & flowability
N/S (small) N/S (plates)
 
a compared under rapid cooling. 
b compared using methanol as the crystallizing solvent. 
c compared under natural cooling using methanol as the crystallizing solvent. 
d compared for particles recrystallized under rapid cooling using methanol as the crystallizing solvent. 
N/S: not significant. 
 
4.1.3 Drug substance quality determining flowability 
All the plate-shaped particles of Compound-A exhibited good powder flow. Since plates should 
contact with each other by face to face, firm agglomeration would occur. As a result, apparent 
particle size and density would increase. This means the decrease in surface area and 
compressibility, therefore the powder would exhibit good flowability. Among these batches, 
better flow was seen when the primary particles were smaller, where apparent particle size was 
inversely larger due to the higher degree of agglomeration. Adhesion force would be dominant 
over the separation force when particles were small. On the other hand, all the needle-shaped 
particles of Compound-A exhibited poor powder flow regardless of the primary particle size. 
They did not form firm agglomerates because the contact between these particles should be point 
to point. As a result, apparent particle size would be the same as primary particle size itself. 
Small particle size and low apparent density mean high surface area and compressibility, 
therefore the powder would exhibit poor flowability. 
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4.2 Dissolution behavior 
4.2.1 Tablet dissolution and powder dissolution 
Dissolution patterns of Compound-A in water are shown in Figure 18. 
Dissolution profiles of Compound-A 300 mg film-coated tablets in water are summarized in 
Table 21. Tablets made from the typical S-batch showed lower dissolution rates than those done 
from the typical M-batch throughout the dissolution test. Since neither the formulation nor the 
manufacturing method was different, something different should exist in the drug substances. 
Dissolution profiles of Compound-A powders and those from physical mixture with lactose (1:1) 
in water are summarized in Table 22 and Table 23, respectively. Contrary to expectations, 
powder dissolution of the S-batch was more rapid than that of the M-batch, probably due to the 
larger surface area. However, the relationship found in the drug products could be reproduced by 
adding the excipient; The powder dissolution of the M-batch was improved but that of the S-
batch was delayed when they were mixed with lactose (monohydrate, milled), a main component 
of the drug product. The surface of dissolution media immediately after starting the powder 
dissolution of Compound-A (hammer-milled) and 1:1 physical mixture with lactose is shown in 
Figure 19. The surfaces of S4 (H) alone and the physical mixture of M4 (H) and lactose were at 
rest, suggesting good wettability of both powders. 
a) Tablet dissolution b) Powder dissolution
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Figure 18 Dissolution patterns of Compound-A in water. a) Tablet dissolution. Sample: Compound-A 
300 mg film-coated tablets, made from M4 (H) or S4 (H). b) Powder dissolution. Sample: 300 
mg of Compound-A powders (hammer-milled), or 600 mg of Compound-A powders from 
physical mixture with lactose (1:1). 
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Table 21 Dissolution profiles of Compound-A 300 mg film-coated tablets in water. 
Time
[min] CL-lower Mean CL-upper SD % RSD CL-lower Mean CL-upper SD % RSD
5 17.5 26.1 34.7 10.7 41.2 11.9 17.7 23.6 7.3 41.4
10 58.2 66.6 75.0 10.5 15.8 47.7 53.7 59.7 7.5 14.0
15 74.1 81.6 89.2 9.5 11.6 62.9 70.6 78.3 9.6 13.6
30 82.3 90.1 97.8 9.7 10.8 80.5 86.0 91.4 6.8 7.9
45 87.0 93.0 99.0 7.5 8.1 81.6 86.9 92.1 6.6 7.6
60 88.4 93.0 97.6 5.8 6.2 83.2 88.0 92.7 5.9 6.7
90 90.6 93.9 97.3 4.2 4.5 85.7 89.7 93.7 5.0 5.5
120 88.2 92.7 97.2 5.6 6.0 89.4 92.1 94.9 3.5 3.7
300 mg film-coated tablet made from S4 (H)
Dissolution rate [%]
300 mg film-coated tablet made from M4 (H)
 
CL: 95 % confidence limit. 
 
Table 22 Dissolution profiles of 300 mg of Compound-A powders in water. 
Time
[min] CL-lower Mean CL-upper SD % RSD CL-lower Mean CL-upper SD % RSD
5 2.7 4.3 5.9 1.4 32.7 20.4 22.7 25.1 2.1 9.2
10 11.9 14.2 16.6 2.1 14.5 49.9 52.5 55.0 2.2 4.3
15 22.8 26.3 29.7 3.0 11.5 75.1 78.1 81.1 2.6 3.4
30 48.2 55.5 62.8 6.5 11.7 96.1 96.5 96.9 0.4 0.4
45 65.6 73.3 80.9 6.8 9.2 97.8 98.2 98.6 0.4 0.4
60 75.8 83.6 91.4 6.9 8.3 98.2 98.4 98.7 0.2 0.2
90 88.1 94.1 100.1 5.3 5.6 99.2 99.6 99.9 0.3 0.3
120 96.9 100.2 103.6 3.0 3.0 98.5 98.7 99.0 0.2 0.2
S4 (H)
Dissolution rate [%]
M4 (H)
 
CL: 95 % confidence limit. 
 
Table 23 Dissolution profiles of 600 mg of Compound-A powders from physical mixture with lactose 
(1:1) in water. 
Time
[min] CL-lower Mean CL-upper SD % RSD CL-lower Mean CL-upper SD % RSD
5 22.0 29.5 37.0 6.6 22.5 5.3 8.5 11.7 2.8 33.5
10 74.5 75.2 76.0 0.7 0.9 26.8 30.2 33.6 3.0 9.9
15 88.8 90.1 91.3 1.1 1.2 46.9 53.0 59.0 5.4 10.1
30 95.8 97.5 99.2 1.5 1.6 74.3 80.2 86.0 5.2 6.4
45 96.5 98.1 99.7 1.4 1.4 85.9 89.9 93.9 3.5 3.9
60 96.6 98.3 100.0 1.5 1.5 92.5 95.2 97.8 2.3 2.5
90 97.0 98.7 100.3 1.5 1.5 103.7 104.2 104.7 0.5 0.4
120 101.3 103.4 105.5 1.8 1.8 104.5 104.8 105.2 0.3 0.3
M4 (H) + Lactose (1:1)
Dissolution rate [%]
S4 (H) + Lactose (1:1)
 
CL: 95 % confidence limit. 
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Figure 19 Surface of dissolution media immediately after starting the powder dissolution of 
Compound-A (hammer-milled) & 1:1 physical mixture with lactose. 
 
4.2.2 Relationship to particle size 
The mixing conditions were investigated microscopically. Scanning electron micrographs of 
Compound-A (hammer-milled) and 1:1 physical mixture with lactose are shown in Figure 20. 
The particle size of lactose was roughly half of the M-batch and twice that of the S-batch. 
Lactose particles adhered to the surface of M-batch particles when mixed. On the other hand, 
most of the lactose particles were covered with S-batch particles. 
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Figure 20 Scanning electron micrographs of Compound-A (hammer-milled) & 1:1 physical mixture 
with lactose. Magnification: 500x. 
 
4.2.3 Drug substance quality determining dissolution behavior 
Lactose is well known to have wetting effect, and therefore the dissolution behavior of 
Compound-A should depend on whether or not lactose could be on the surface of individual 
particles. Since the apparent particle size of M-batches were large due to the high degree of 
agglomeration as well as the original primary particle size, lactose particles always existed on the 
surface of M-batch particles, where the improvement on wettability by lactose could be expected. 
On the other hand, S-batches could not receive benefit from lactose because of the small 
apparent particle size. Furthermore, agglomeration occurred due to the relatively slow 
dissolution kinetics of lactose, and thus the dissolution of Compound-A was delayed. 
52 
5. CONCLUSIONS 
It can be concluded that particle shape is the critical factor determining the powder flow of 
Compound-A. Plate-like shape facilitates firm agglomeration and results in good powder flow, 
unlike needle-like shape. The relative particle size of Compound-A to other excipients is 
considered responsible for the dissolution behavior. 
Although recrystallization studies reported herein were not necessarily comprehensive, it is 
recommendable that rapid cooling should be employed to promote agglomeration. Even more 
importantly, complete dissolution of starting material before cooling has to be assured to avoid 
producing elongated particles, which would exhibit poor powder flow. 
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PART 2: MICRONIZATION AND POLYMORPHIC CONVERSION OF 
TOLBUTAMIDE AND BARBITAL BY RAPID EXPANSION OF 
SUPERCRITICAL SOLUTIONS 
1. ABSTRACT 
Rapid expansion of supercritical solutions (RESS) was applied to tolbutamide and barbital. The 
solubility in supercritical CO2 was determined to estimate the extraction efficiency roughly by a 
simple method and accurately by a direct spectrophotometric technique. The latter revealed that 
the solubility of tolbutamide was a function of applied pressure and temperature and was 
proportional to the pressure. No significant difference in solubility between polymorphic Forms I 
and II of tolbutamide was detected. Tolbutamide and barbital particles produced by the RESS 
were characterized by size distribution measurement, polymorph identification and 
morphological evaluation. Significant size reduction to micron or sub-micron level with narrow 
size distribution was achieved, while conventional mechanical grinding had only slight effect. 
The particle size was greatly affected by both extraction and expansion conditions. The lower the 
extraction temperature was, the smaller was the mean particle size. Higher extraction pressure 
resulted in smaller mean particle size when compared at the same extraction temperature. The 
mean particle size was reduced by lowering the spray nozzle temperature, by lowering the 
expansion chamber temperature, by increasing the CO2 amount per spray, and by increasing the 
exhaust gas flow rate. The RESS processing realized the polymorphic conversion as well. As for 
tolbutamide, three polymorphs (Forms I, II and IV) out of four could be produced by changing 
the extraction conditions, and in the case of barbital one polymorph (Form II) out of three was 
produced consistently. 
KEYWORDS Supercritical fluid, RESS, Micronization, Polymorphic Conversion, 
Tolbutamide, Barbital 
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2. INTRODUCTION 
Most of the newly developed active pharmaceutical ingredients are poorly soluble or insoluble in 
aqueous media. Increasing surface area of such pharmaceuticals by particle size reduction is one 
of the clues to improve the dissolution, absorption and therefore bioavailability 1, 2. Grinding and 
spray-drying are the major techniques for the size reduction, however, heat- or mechanical 
stress-induced degradation of the material and the difficulty of removing residual organic 
solvents often limit the application, respectively. Furthermore, the size distribution is usually 
broad and hardly reach to micron or sub-micron level. 
Supercritical fluid has been applied to various industries utilizing the unique characteristics. It 
can dissolve solid materials due to the high density close to liquid. On the other hand, the density 
can vary depending on the applied pressure and temperature, and rapid diffusion like gas can 
occur 3 . Recently, particle design using supercritical fluid is of great interest in the 
pharmaceutical industry 4 ; such as microencapsulation of peptides or genes 5 , 6 , suspension 
preparation 7, and fluidized-bed coating 8. 
Several techniques to micronize the material utilizing supercritical fluids are known 4; rapid 
expansion of supercritical solutions (RESS), gas anti-solvent (GAS), aerosol solvent extraction 
system (ASES) and solution enhanced dispersion of solids (SEDS). Among them, the RESS 
method is the only way to process the material without organic solvents. In the RESS process, 
the solute is dissolved in a supercritical fluid and the supercritical solution is rapidly expanded 
by spraying it into normal pressure throughout a nozzle. Rapid change of the supercritical 
solution into gas phase induces high supersaturation of the solute and therefore micronized 
material will precipitate. The level of supersaturation on the RESS process is much higher than 
that on spray-drying or GAS 3, 9. The high level of supersaturation predominantly induces the 
nucleation over the crystal growth, thus results in small particles with narrow size distribution. 
As a supercritical fluid, carbon dioxide (CO2) has commonly been used because of its mild 
critical pressure and temperature (7.4 MPa, 31 °C). Supercritical CO2 is advantageous to the 
environment due to the non-toxic and easily recycled properties and to the application for heat-
sensitive pharmaceuticals 10 . Micronization of pharmaceuticals by the RESS method was 
reported on griseofulvin 11, ibuprofen 12, progesterone and medroxyprogesterone 13. The mean 
particle size of the drugs produced by the RESS technique drastically reduced to micron order or 
sometimes to sub-micron level. The limitation of the RESS method is that the material must 
dissolve in the supercritical fluid. 
An important factor influencing dissolution behavior other than the particle size is the 
polymorphic form. In general, metastable forms show higher solubility than the stable form. 
Therefore polymorphic conversion to a metastable form is often taken to improve the dissolution 
behavior of poorly water-soluble drugs, where recrystallization from organic solution is 
commonly used. A unique approach utilizing supercritical fluids is the preparation of 
polymorphs. Carbamazepine microparticles were produced by the RESS method, and different 
polymorphs were obtained depending on the operating conditions 14 . Micronization of 
phenylbutazone by the RESS processing resulted in the formation of a metastable form 15. 
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The objective of this study was to gain an insight into the RESS method as one-step processing 
for micronization and polymorphic conversion. For this purpose, the influence of operating 
conditions during the RESS process on particle size and polymorphic form was investigated. 
Tolbutamide and barbital were employed as model compounds since both drugs are poorly 
water-soluble and the advantages of the metastable forms in solubility and dissolution behavior 
have been reported 16, 17. 
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3. MATERIALS AND METHODS 
3.1 Materials 
Tolbutamide was purchased from Nacalai Tesque, Inc. (Kyoto, Japan), Sigma Aldrich Japan K.K. 
(Tokyo, Japan) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan), and used as received. 
The intact tolbutamide was Form I (Nacalai and Sigma) or Form II (Wako). Form I from Nacalai 
and Form II from Wako were used for the solubility determination, and Form I from Sigma was 
used as starting material for the RESS experiments. Barbital was purchased from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan) and was a mixture of Forms I and II. For the RESS 
experiments the intact barbital was converted to pure Form I by storing in supercritical CO2 
atmosphere at 26 MPa and 60 °C for 3 h before use. Liquid CO2 (> 99.5 %) was purchased from 
Ozawa Sanso Co., Ltd. (Chiba, Japan). Ethanol was of reagent grade and used as received. To 
compare with the RESS processing, ground samples of intact drugs were prepared by using a 
vibration rod mill (TI-200, CMT, Tokyo, Japan). 
3.2 Apparatus and settings 
A supercritical fluid operating system, based on the rapid expansion of supercritical solutions 
(RESS) method, was used (Figure 21: SC-Sprayer, Nikkiso Co., Ltd., Tokyo, Japan). The 
maximum tolerable pressure and temperature of the whole system were 29 MPa and 80 °C, 
respectively. The starting material was loaded in a temperature-controlled reaction vessel of 90 
mL inner volume. Liquid CO2 was compressed and heated to above the critical pressure and 
temperature, 7.4 MPa and 31 °C, and then introduced into the reaction vessel by using a pump 
(NP-AX-40J, Nihon Seimitsu Kagaku Co., Ltd., Tokyo, Japan). The material was kept under 
supercritical CO2 atmosphere at a constant pressure and temperature while magnetic-stirring 
(PC-420, Corning, Inc., NY, USA). After the extraction, a constant amount of supercritical CO2 
containing dissolved material was sprayed, via a stainless steel tubing and a tungsten carbide 
spray tip (UniJet, Spraying Systems Co., Japan, Tokyo, Japan: internal diameter = 0.23, 0.33 or 
0.66 mm, length = 9.5 mm), into an expansion chamber of 12 L inner volume. Rapid change of 
the supercritical solution into gas phase could induce high supersaturation of the solute and 
therefore micronized material would precipitate. The CO2 gas was exhausted by using an air 
compressor (0.75LP-7S·T, Hitachi, Ltd., Tokyo, Japan) and the flow rate was adjusted with an 
ejector cock to collect precipitated material on a 0.8 µm glass fiber filter (Millipore Corporation, 
MA, USA) or a 0.45 µm membrane seal (MilliWrapTM, Millipore Corporation, MA, USA) 
placed on the bottom flange of the expansion chamber. The temperature of the expansion 
chamber was controlled by covering with a silicone rubber heater (SR, Mitutoyo Tusyo 
Corporation, Tokyo, Japan), if need be. 
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Figure 21 Schematic diagram of RESS apparatus (SC-Sprayer). The gray zone indicates supercritical 
CO2 atmosphere. 
 
3.3 Determination of solubility of tolbutamide and barbital in supercritical CO2 
A sufficient amount of the drug (0.2 g) was put into a glass vial and set in the reaction vessel. 
The drug was kept under supercritical CO2 atmosphere at 26 MPa and 60 °C for 1 h, and 0.2 mol 
CO2 equivalent was sprayed into ethanol, which was used as a solvent for assay. Solubility of 
drugs in supercritical CO2, expressed as a mole fraction, was determined spectrophotometrically 
(UV-160, Shimadzu Corporation, Kyoto, Japan). 
Separately, the solubility was determined by a direct spectrophotometric technique using a 
pressure-resistant optical cell unit. UV-visible spectra of the drug supercritical CO2 solution in 
an optical cell, made of SUS 316, were measured by a spectrophotometer (V-550, Jasco 
Corporation, Tokyo, Japan) through a pair of sapphire windows and fiber optics. The optical path 
length was 2 mm and the inner volume was 5 mL. The maximum working pressure and 
temperature were 30 MPa and 100 °C, respectively. After the sample loading, the cell was 
evacuated for 1 h to remove inside air completely, then CO2 was introduced. After saturation was 
reached (2 h each), UV-visible spectra at various pressure (10 – 30 MPa) and temperature (40 – 
60 °C) were measured. The solubility was determined based on the integrated Lambert-Beer’s 
law (Equation [7]); 
∫∫ = 2
1
2
1
λ
λ
λ
λ
λελ dClAd
 [7] 
where A is an absorbance, C is a solute concentration, l is an optical path length, ε is a solute 
molar absorptivity and λ is a wavelength. λ1 and λ2 are lower and upper limits for integration, 
respectively 18. By integrating the specific spectra for the calculation, accurate solubility could be 
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determined when compared to the conventional equation at a single and fixed wavelength. This 
calculation method also enabled to reduce the influence of the CO2 density on the spectrum shift 
and the change in the solute molar absorptivity. 
3.4 Micronization of tolbutamide and barbital by rapid expansion of supercritical 
solutions (RESS) 
A sufficient amount of the drug (1.0 g) was put into a 30 mL glass vial, covered with a 0.45 µm 
membrane seal (MilliWrapTM, Millipore Corporation, MA, USA), and set in the reaction vessel. 
The drug was kept under supercritical CO2 atmosphere at a constant pressure and temperature 
until solubility saturation was reached (tolbutamide: 3 h; barbital: 1 h). A constant amount of 
supercritical CO2 containing dissolved drug was sprayed into the expansion chamber. Pressure 
loss on spraying inside the reaction vessel was compensated by introducing pressure and 
temperature-controlled supercritical CO2 at a flow rate of 40 mL/min. It was not possible to 
visually observe any potential precipitation in the reaction vessel due to the pressure loss because 
an excess amount of starting material was put into the vessel and therefore a solid fraction 
always existed together. Nevertheless, it could be assumed that there would be no precipitation 
before and during pressure recovery since the inside of the reaction vessel was in a supercritical 
condition even after spraying and pressure loss on spraying was recovered in several seconds. 
Thirty seconds after the pressure recovery another part of supercritical solution was sprayed. 
Repeating this cycle 100 times, micronized drug particles were collected. The influence of 
extraction conditions on particle size and polymorphic form was investigated for both drugs, and 
the size reduction effect was further optimized using barbital by varying the expansion 
conditions. Process variables on extraction were pressure (18 – 26 MPa) and temperature (32 – 
80 °C), and those on expansion were spray nozzle diameter (0.23 – 0.66 mm), spray nozzle 
temperature (32 – 80 °C), CO2 amount per spray (0.07 – 0.28 mol equivalent), expansion 
chamber temperature (30 – 80 °C), distance between spray nozzle and filter (7 – 30 cm) and 
exhaust gas flow rate (0 – 4.3 m3/h). 
3.5 Characterization of tolbutamide and barbital particles 
3.5.1 Size distribution measurement by laser diffractometry and dynamic light 
scattering 
Particle size based on the volume distribution was measured by laser diffractometry on 
Microtrac FRA, ranging 0.1 – 700 µm (Nikkiso Co., Ltd., Tokyo, Japan) or by dynamic light 
scattering on Microtrac UPA150, ranging 0.003 – 6 µm (Nikkiso Co., Ltd., Tokyo, Japan). 
Appropriate amounts of specimens were dispersed in water by ultrasound for the measurement. 
3.5.2 Polymorph identification by X-ray powder diffractometry (XRPD) and 
differential scanning calorimetry (DSC) 
Polymorphic forms were investigated by using an X-ray powder diffractometer (MiniFlex, 
Rigaku Corporation, Tokyo, Japan) equipped with a Ni-filtered Cu-anode (A-20Cu, Toshiba 
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Corporation, Tokyo, Japan; 30 kV, 15 mA). Specimens were gently ground with an agate mortar 
and filled in a glass sample plate. The XRPD patterns were recorded at a scanning speed of 2θ = 
4 °/min over a range of 2θ = 2 – 35 °. 
Supplemental evidence on the polymorphic form was taken with a differential scanning 
calorimeter (DSC6200, Seiko Instruments Inc., Chiba, Japan). About 3 mg of specimens were 
filled in a crimped aluminum pan and the DSC traces were recorded at a heating rate of 10 
°C/min over a range of 30 – 220 °C (tolbutamide) or 5 °C/min over a range of 30 – 250 °C 
(barbital) under the nitrogen atmosphere flowing at 60 mL/min. The onset temperature and 
enthalpy of melting and transition peaks were calculated. 
3.5.3 Morphological evaluation by scanning electron microscopy (SEM) 
Particle morphology was investigated by using a scanning electron microscope (S-4300, Hitachi, 
Ltd., Tokyo, Japan). Specimens were mounted on a metal stub with a conductive double-sided 
adhesive tape and coated with Au-Pd (6:4) by an ion sputter (JEC-550, JEOL Ltd., Tokyo, 
Japan) prior to the observation. The SEM photographs were taken at 10 – 20 kV and 
magnifications of 60 – 5000 x. 
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4. RESULTS AND DISCUSSION 
4.1 Solubility of tolbutamide and barbital in supercritical CO2 
Solubility of drugs in supercritical CO2 affects the extraction efficiency of micronized products 
on the RESS process, while the relationship between the solubility and chemical structure has 
not fully been understood. To estimate the solubility, the same apparatus as the RESS processing 
was employed. Table 24 summarizes the solubility of tolbutamide and barbital in supercritical 
CO2 measured after storing at 26 MPa and 60 °C for 1 h, combined with the data of some other 
drugs obtained in-house under the same conditions. Drugs having lower melting temperature 
tended to have higher solubility in supercritical CO2, although there were some exceptions. 
Tolbutamide and barbital showed relatively high solubility (6.89 x 10-5 and 3.57 x 10-5, 
respectively) and appeared to be suitable for the RESS experiments. 
Table 24 Solubility of drugs in supercritical CO2. 
Drug Mol. weight Melting temp. Solubility in supercritical CO2
(g/mol) a (°C) a (mole fraction, x 10-5) b
Phenytoin 252.27 297 0.26
Barbituric acid 128.09 248 0.46
Naproxen 230.26 153 0.54
Flurbiprofen 244.27 111 1.04
Aspirin 180.16 135 1.40
Phenobarbital 232.24 176 2.20
Mephobarbital 246.27 176 2.71
Barbital 184.19 190 3.57
Allobarbital 208.22 172 4.21
Hexobarbital 236.27 146 4.25
Phenylbutazone 308.38 105 6.78
Tolbutamide 270.35 129 6.89
Ibuprofen 206.28 76 11.30  
a quoted from The Merck Index 19. The mean of the upper and lower limits, if provided as a range. 
b measured after storing at 26 MPa and 60 °C for 1 h. 
 
Tolbutamide, commonly used as an antidiabetic or a hypoglycemic agent, is known to exist as at 
least four polymorphs, Forms I, II, III and IV 17. The crystal forms of tolbutamide available on 
the market were Form I (stable form) and Form II. To determine the starting material for the 
RESS experiments, the solubilities of tolbutamide Forms I and II were investigated in detail by a 
direct spectrophotometric technique. The solubility of tolbutamide in supercritical CO2 was a 
function of applied pressure and temperature and was proportional to the pressure as shown in 
Figure 22. No significant difference in solubility between Forms I and II of tolbutamide was 
detected. Meanwhile, gradual transition of Form II into Form I under the supercritical CO2 
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atmosphere was found. Taking those findings into consideration we decided to use stable Form I 
for a series of the RESS experiments. 
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Figure 22 Solubility of tolbutamide in supercritical CO2 (direct spectrophotometric measurement). 
 
Barbital, a sedative or a hypnotic, exists as at least three polymorphs 20. The crystal form of 
barbital purchased was found as a mixture of Form I (stable form) and Form II. For the RESS 
experiments the intact barbital was converted to pure Form I by storing in supercritical CO2 
atmosphere at 26 MPa and 60 °C for 3 h before use. 
4.2 Characterization of tolbutamide and barbital particles micronized by RESS 
processing 
4.2.1 Influence of extraction conditions on particle size 
The influence of extraction pressure (18 – 26 MPa) and temperature (32 – 80 °C) on particle size 
of tolbutamide and barbital was investigated under the fixed expansion conditions. The results 
for tolbutamide and barbital are summarized in Table 25 and Table 26, respectively. Significant 
size reduction was achieved by the RESS processing. The mean particle size of intact 
tolbutamide and barbital was 126 and 204 µm, respectively, and the size of RESS processed 
particles was all micron or sub-micron level while the mechanical grinding had only slight effect. 
Figure 23 and Figure 24 represent typical patterns of the particle size distribution of tolbutamide 
and barbital, respectively. It is apparent that the RESS processing made the size distribution 
narrower. It was found for both drugs that the lower the extraction temperature was, the smaller 
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was the mean particle size. Higher extraction pressure resulted in smaller mean particle size 
when compared at the same extraction temperature. The smallest particles were thus obtained 
when the RESS process was operated at 26 MPa and 32 °C (mean particle size: tolbutamide = 
1.64 µm; barbital = 0.69 µm). 
Table 25 Influence of extraction conditions on particle size and polymorphic form of tolbutamide. 
Mean
particle
Pressure Temp. size Polymorphic Onset Enthalpy Onset Enthalpy Onset Enthalpy
(MPa) (°C) (µm) form (°C) (J/g) (°C) (J/g) (°C) (J/g)
Intact, from Sigma
(starting material a )
Ground b - - 29.7 d I
18 32 n.t. e n.t. e
18 40 1.98 f (I +) II g n.d. n.d. 56.4 1.1 115.5 18.2
18 60 3.58 f I + II n.d. n.d. 73.1 0.1 117.8 20.0
18 80 3.74 f I (+ II) h n.d. n.d. 71.7 0.1 119.2 19.2
26 32 1.64 f II n.d. n.d. 63.5 1.7 113.8 17.0
26 40 1.91 f II n.d. n.d. 56.7 1.1 116.9 19.3
26 50 1.95 f II n.d. n.d. 66.6 9.0 120.3 78.0
26 60 2.13 f IV n.d. n.d. 61.5 9.5 119.0 81.1
26 70 2.25 f IV n.d. n.d. 59.4 1.7 121.4 19.5
26 80 3.30 f IV 49.1 -1.4 76.5 0.1 116.4 19.1
Intact, from Wako - - n.t. II n.d. n.d. 97.4 10.8 125.4 88.6
Extraction DSC
conditions XRPD
-
IV - II transition
n.t.
n.d.126 d I n.d.
II - I transition Form I melting
n.t. e
Sample
127.1 99.9n.d. n.d.
RESS c
-
 
a The intact tolbutamide from Sigma was used as the starting material of the RESS process. 
b The intact tolbutamide was mechanically ground for 30 min by using a vibration rod mill. 
c The expansion conditions were fixed; spray nozzle diameter = 0.33 mm, spray nozzle temperature = same 
temperature as extraction, CO2 amount per spray = 0.19 mol equivalent, expansion chamber temperature = 30 °C, 
distance between spray nozzle and filter = 30 cm, exhaust gas flow rate = 4.3 m3/h. 
d measured by laser diffractometry. 
e not tested, due to the low yield. 
f measured by dynamic light scattering. 
g Form II dominant. 
h Form I dominant. 
n.t.: not tested; n.d.: not detected. 
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Table 26 Influence of extraction conditions on particle size and polymorphic form of barbital. 
Mean
particle
Pressure Temp. size Polymorphic Onset Enthalpy Onset Enthalpy Onset Enthalpy
(MPa) (°C) (µm) form (°C) (J/g) (°C) (J/g) (°C) (J/g)
Intact - - 204 d I + II n.d. n.d. 130.3 4.1 189.6 142.4
Ground a - - 110 d I + II n.d. n.d. 130.3 3.6 189.9 127.1
Starting material b - - n.t. I n.d. n.d. n.d. n.d. 189.5 137.7
18 32 1.27 e II n.d. n.d. 115.3 2.3 188.9 105.9
18 40 1.31 e II n.d. n.d. 123.8 3.5 188.9 135.8
18 50 1.81 e II n.d. n.d. 121.2 3.7 186.2 114.9
18 60 4.18 e II (+ IV) f n.d. n.d. 119.3 3.2 188.4 133.2
26 32 0.69 e II n.d. n.d. 112.0 2.4 187.9 92.9
26 40 0.84 e II n.d. n.d. 114.3 3.2 187.3 96.2
26 50 1.32 e II n.d. n.d. 119.0 2.9 187.7 110.2
26 60 2.85 e II n.d. n.d. 130.6 1.9 187.5 90.4
DSC
IV - II transition II - I transition Form I meltingXRPDSample
RESS c
Extraction
conditions
 
a The intact barbital was mechanically ground for 30 min by using a vibration rod mill. 
b The intact barbital, a mixture of Forms I and II, was converted to pure Form I by storing in supercritical CO2 
atmosphere at 26 MPa and 60 °C for 3 h and used as the starting material of the RESS process. 
c The expansion conditions were fixed; spray nozzle diameter = 0.33 mm, spray nozzle temperature = same 
temperature as extraction, CO2 amount per spray = 0.19 mol equivalent, expansion chamber temperature = 30 °C, 
distance between spray nozzle and filter = 30 cm, exhaust gas flow rate = 4.3 m3/h. 
d measured by laser diffractometry. 
e measured by dynamic light scattering. 
f Form II dominant. 
n.t.: not tested; n.d.: not detected. 
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Figure 23 Particle size distribution patterns of tolbutamide. a: intact. b: ground for 30 min by using a 
vibration rod mill. c: RESS-processed at extraction conditions of 18 MPa and 80 °C. d: RESS-
processed at extraction conditions of 26 MPa and 32 °C. 
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Figure 24 Particle size distribution patterns of barbital. a: intact. b: ground for 30 min by using a 
vibration rod mill. c: RESS-processed at extraction conditions of 18 MPa and 60 °C. d: RESS-
processed at extraction conditions of 26 MPa and 32 °C. 
 
In general, higher solubility of the solute in supercritical fluid is given at higher extraction 
pressure and temperature 12, 21, 22. Actually, the highest solubility of tolbutamide in supercritical 
CO2 was given at the highest pressure and temperature (Figure 22). The high solubility in 
supercritical CO2 means high level of supersaturation during the expansion. The high level of 
supersaturation predominantly induces the nucleation over the crystal growth, thus results in 
small particles with narrow size distribution. In this context, it seemed reasonable that higher 
extraction pressure resulted in smaller particles. Moreover, higher pressure should contribute 
producing smaller droplets when sprayed. On the other hand, another explanation would be 
needed for the influence of extraction temperature since the results were the opposite. Rapid 
expansion of supercritical fluid induces rapid drop in temperature (adiabatic expansion), which is 
also related to the level of supersaturation. Reverchon and Pallado reported that lower expansion 
temperature was favorable to produce larger temperature difference before and after expansion 23. 
The impact of the temperature difference, which could differ with the expansion conditions, was 
considered dominant over the solubility difference under the apparatus and settings employed in 
this study. 
4.2.2 Influence of expansion conditions on particle size 
The influence of expansion conditions on particle size was investigated using barbital. The 
process variables were spray nozzle diameter, spray nozzle temperature, CO2 amount per spray, 
expansion chamber temperature, distance between spray nozzle and filter, and exhaust gas flow 
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rate. The extraction pressure and temperature were fixed at 26 MPa and 32 °C, respectively. The 
results are summarized in Table 27. 
Table 27 Influence of expansion conditions on particle size of barbital a. 
Mean
Spray Spray CO2 Expansion Distance Exhaust gas particle
nozzle nozzle amount chamber spray nozzle flow rate size
diameter temp. per spray temp. vs. filter
(mm) (°C) (mol) (°C) (cm) (m3/h) (µm) b
0.23 32 0.19 30 30 4.3 0.77
0.33 32 0.19 30 30 4.3 0.69 c
0.66 32 0.19 30 30 4.3 0.79
0.33 32 0.19 30 30 4.3 0.69 c
0.33 40 0.19 30 30 4.3 1.22
0.33 60 0.19 30 30 4.3 1.57
0.33 32 0.07 30 30 4.3 1.77
0.33 32 0.19 30 30 4.3 0.69 c
0.33 32 0.28 30 30 4.3 0.54
0.33 32 0.19 30 30 4.3 0.69 c
0.33 32 0.19 40 30 4.3 1.19
0.33 32 0.19 60 30 4.3 1.57
0.33 32 0.19 80 30 4.3 1.77
0.33 32 0.19 30 7 4.3 0.75
0.33 32 0.19 30 14 4.3 0.54
0.33 32 0.19 30 30 4.3 0.69 c
0.33 32 0.19 30 30 0.0 1.83
0.33 32 0.19 30 30 2.2 0.93
0.33 32 0.19 30 30 4.3 0.69 c
Expansion conditions
 
a The intact barbital, a mixture of Forms I and II, was converted to pure Form I by storing in supercritical CO2 
atmosphere at 26 MPa and 60 °C for 3 h and used as the starting material of the RESS process. The extraction 
conditions were fixed; extraction pressure = 26 MPa, extraction temperature = 32 °C. 
b measured by dynamic light scattering. 
c the same data as in Table 26. 
n.t.: not tested. 
 
The mean particle size of barbital was reduced by lowering the spray nozzle temperature, by 
lowering the expansion chamber temperature, and by increasing the CO2 amount per spray. High 
spray nozzle temperature or high expansion chamber temperature was reported to increase the 
particle size 9, 24. Heating the spray nozzle or expansion chamber can inhibit rapid drop in 
temperature during the expansion of supercritical solution. Increasing the CO2 amount per spray 
should be related to the improvement of the diffusion efficiency of sprayed supercritical solution. 
Increasing the exhaust gas flow rate resulted in particle size reduction. Reducing the pressure 
inside the extraction chamber has been reported to reduce the particle size 13. Consecutive 
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spraying may accumulate residual CO2 inside the extraction chamber, which can inhibit the rapid 
expansion of supercritical solution. 
The influence of the other two process variables, spray nozzle diameter and distance between 
spray nozzle and filter, were not significant. The size of spray nozzle has been reported less 
influential when compared to the shape 2425. It probably means that the diffusion manners of 
sprayed supercritical solution were almost the same within the tested range of 0.23 – 0.66 mm. 
The distance between spray nozzle and filter can affect the crystal growth and agglomeration 
behavior of primary particles. A large number of mathematical and experimental models have 
been reported 23, 26, 27. Although the influence of distance between spray nozzle and filter on 
particle size was not so significant in this study, the best result was obtained at the intermediate 
distance of 14 cm, indicating the existence of optimum distance. 
The influence of expansion conditions as well as extraction conditions on particle size presented 
here was similar to our previous report on phenylbutazone 15; The mean particle size of 
phenylbutazone was reduced by lowering the spray nozzle temperature, by increasing the CO2 
amount per spray, and by increasing the exhaust gas flow rate. 
The mean particle size of barbital was successfully reduced to 0.54 µm by the process 
optimization; extraction pressure = 26 MPa, extraction temperature = 32 °C, spray nozzle 
diameter = 0.33 mm, spray nozzle temperature = 32 °C, CO2 amount per spray = 0.28 mol 
equivalent, expansion chamber temperature = 30 °C, distance between spray nozzle and filter = 
30 cm, and exhaust gas flow rate = 4.3 m3/h. 
4.2.3 Influence of extraction conditions on polymorphic form of tolbutamide 
The influence of extraction pressure (18 – 26 MPa) and temperature (32 – 80 °C) on 
polymorphic form of tolbutamide was investigated. The results are summarized in Table 25, 
where the polymorphic forms were assigned based on the XRPD and DSC data reported by 
Kimura et al. 17. It was found that the crystalline forms could differ with the extraction 
conditions on the RESS process. Figure 25 represents the XRPD patterns of tolbutamide, 
combined with the DSC traces. At a low extraction pressure of 18 MPa, the RESS processed 
samples exhibited characteristic X-ray diffraction peaks of both Form I (2θ = 8.7, 12.1 and 19.9 
°) and Form II (2θ = 10.3, 11.3 and 19.6 °). From the comparison of X-ray diffraction intensities, 
the RESS processed samples were recognized as mixtures of Forms I and II, even Form II was 
dominant at lower temperature and Form I at higher. The samples prepared at 40 and 80 °C were 
mainly consisted of Forms II and I, respectively. Metastable forms (Forms II and IV) were 
possible to be produced at a high extraction pressure of 26 MPa. Form II characteristic X-ray 
diffraction peaks were observed when prepared at 50 °C or lower (Figure 25c), as seen in the 
intact tolbutamide purchased from Wako (Figure 25b: Form II). On the other hand, Form IV 
characteristic X-ray diffraction peaks, 2θ = 10.6, 18.0 and 18.9 °, were given when prepared at 
60 °C or higher (Figure 25d). 
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Figure 25 XRPD patterns (left) and DSC traces (right) of tolbutamide. a, a’: intact from Sigma (Form I; 
starting material of the RESS process). b, b’: intact from Wako (Form II). c, c’: RESS-processed 
at extraction conditions of 26 MPa and 32 °C. d, d’: RESS-processed at extraction conditions of 
26 MPa and 80 °C. The Y-axes of the DSC traces were normalized by the weight of each sample. 
 
The DSC data were consistent with the results on XRPD. The RESS processed samples prepared 
at low pressure (18 MPa) or low temperature (50 °C or lower) showed Form II characteristic two 
endothermic peaks (Figure 25c’), as seen in the DSC trace of intact tolbutamide purchased from 
Wako (Figure 25b’: Form II). The first small peak observed at 56.4 – 73.1 °C was considered to 
be the transition of Form II to I. The second peak detected at 113.8 – 120.3 °C corresponded to 
the melting of Form I, as seen at 127.1 °C in intact tolbutamide purchased from Sigma (Figure 
25a’: Form I). In addition to those two endothermic peaks, the RESS sample prepared at 26 MPa 
and 80 °C exhibited an exothermic peak at 49.1 °C (Figure 25d’). This peak was due to the 
transition of Form IV to II. Although the RESS samples prepared at 26 MPa and 60 or 70 °C 
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were supposed to show the same exothermic peak considering the results on XRPD (Form IV), 
the peak was not detected as it was very small and close to the detection limit under the 
operation conditions in this study. The RESS processed samples showed lower temperature and 
smaller enthalpy on both the transition of Form II to I and the melting of Form I when compared 
with intact tolbutamide. In general, size reduction sometimes results in melting point depression. 
Actually, Bettini et al. reported that the melting point depression of acetylsalicylic acid observed 
for RESS powders with respect to the commercial material could be attributed to the dramatic 
decrease of particle size as a consequence of micronization 28 . Similarly, significant size 
reduction of tolbutamide on the RESS processing in this study could be a reason for the lower 
melting temperature. The lower transition temperature might be also related to the particle size. 
The enthalpies of Form I melting of the RESS samples were about 20 % of those of the 
commercial products. Considering the difference in overall X-ray diffraction intensities, the 
degree of crystallinity of the RESS samples might be low. Exceptions were the RESS samples 
prepared at 26 MPa and 50 °C (Form II) or 60 °C (Form IV). The enthalpies of the Form I 
melting as well as the Form II to I transition were almost equivalent to those of the commercial 
products. It is interesting that those samples were prepared around the borderline determining 
Form II or IV, but the reason has not been clarified yet. The reduced crystallinity was not always 
regarded as worse since enhanced dissolution could be expected 29. 
Three polymorphs out of four could be produced by the RESS processing. The level of 
supersaturation of the solute in supercritical fluid during the expansion could affect not only the 
particle size but also the polymorphic form 14, 15. In this study, Form II was dominant at lower 
extraction temperature where the level of supersaturation was considered higher and thus smaller 
particles were produced. Form I came into existence at low pressure and high temperature (18 
MPa, 80 °C) where the level of supersaturation was considered lowest among the tested 
conditions. Considering these findings, rapid precipitation due to the high level of 
supersaturation may be preferable to produce Form II (metastable form), while slow precipitation 
kinetic would be advantageous to produce Form I (stable form). Form IV (metastable form) 
could be produced at intermediate conditions (26 MPa, 60 – 80 °C). The residue in the reaction 
vessel stayed Form I regardless of the extraction conditions. 
4.2.4 Influence of extraction conditions on polymorphic form of barbital 
While there are various opinions on the polymorphism of barbital, at least three polymorphs, 
Forms I, II and IV, seem to exist 20. In the same way as tolbutamide, the influence of extraction 
pressure (18 – 26 MPa) and temperature (32 – 60 °C) on polymorphic form of barbital was 
investigated. The results are summarized in Table 26, where the polymorphic forms were 
assigned referring to the XRPD and DSC data reported by Sekiguchi et al. 20. Figure 26 
represents the XRPD patterns of barbital, combined with the DSC traces. The intact barbital 
exhibited a mixed X-ray diffraction pattern of Forms I and II (Figure 26a). The sample used as 
the starting material of the RESS process proved to be Form I as the characteristic X-ray 
diffraction peaks of Form II, 2θ = 15.4, 16.6 and 31.2 °, were not detected while Form I 
characteristic peaks, 2θ = 6.5, 11.4, 16.3 and 17.3 °, were clearly seen (Figure 26b). All the 
RESS processed samples gave Form II characteristic peaks at 2θ = 15.4 and 16.6 ° (Figure 26c). 
Only the sample prepared at 18 MPa and 60 °C showed small X-ray diffraction peaks at 2θ = 7.7 
and 13.5 °, which were characteristic of Form IV, besides the Form II origin (Figure 26d). 
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Figure 26 XRPD patterns (left) and DSC traces (right) of barbital. a, a’: intact (Forms I + II). b, b’: 
stored in supercritical CO2 atmosphere at 26 MPa and 60 °C for 3 h (Form I; starting material of 
the RESS process). c, c’: RESS-processed at extraction conditions of 26 MPa and 32 °C. d, d’: 
RESS-processed at extraction conditions of 18 MPa and 60 °C. The Y-axes of the DSC traces 
were normalized by the weight of each sample. 
 
Supplemental evidence on the polymorphic form was taken with DSC. The sample used as the 
starting material of the RESS process showed a single endothermic peak at 189.5 °C on the DSC 
trace, which corresponded to the melting of Form I (Figure 26b’). All the RESS processed 
samples as well as the intact and ground barbital, mixtures of Forms I and II, showed a small 
endothermic peak at 112.0 – 130.6 °C followed by another endothermic peak at 186.2 – 188.9 °C 
(Figure 26a’, Figure 26c’ & Figure 26d’). The first and second peaks corresponded to the 
transition of Form II to I and the following melting of Form I, respectively. Form IV 
characteristic endothermic peak was not detected even on the DSC trace of the sample prepared 
at 18 MPa and 60 °C, probably due to the small existence ratio. 
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The extraction conditions hardly affected the polymorphic form of barbital. Metastable Form II 
was dominant on the RESS processing under a wide range of operating conditions, although 
slight contamination of another metastable form, Form IV, could occur at 18 MPa and 60 °C. All 
the RESS conditions employed in this study were considered rapid enough to produce metastable 
forms. Especially, higher level of supersaturation seemed to be preferable to produce Form II, 
and relatively lower level of supersaturation, namely a combination of low pressure and high 
temperature on extraction, would be advantageous to produce Form IV. The residue in the 
reaction vessel was determined as Form I. 
Apart from the micronization, it was possible to convert a mixture of Forms I and II of barbital 
into pure Form I by simply storing in supercritical CO2 atmosphere. Grabowska & Kaliszan 
mentioned that individual polymorphic forms evolved into the stable form in given conditions 16. 
The treatment might be of great interest for pharmaceutical industry to produce a pure form or to 
prevent polymorphic transition during storage, which could alter the solubility and therefore 
bioavailability. Bettini et al. reported the polymorphic transition of carbamazepine from a 
mixture of Forms I and III into pure Form III in supercritical CO2 30. They ascribed it to the 
solubilization of Form III followed by the crystallization of Form I, as Form III had higher 
solubility in supercritical CO2 than Form I. Tozuka et al. reported the formation of a new 
polymorph of deoxycholic acid by supercritical CO2 treatment 31. They suggested the possibility 
of solution-mediated physical transformation among polymorphs and/or crystallization after 
dissolution in supercritical CO2. Polymorphic transition of barbital might occur during extraction 
or during depression to normal pressure at the end of experiments. Anyway, polymorphic 
transition and/or precipitation in the reaction vessel should be a slow reaction when compared to 
those at the RESS spraying, and therefore stable Form I would be favorable for the residue in the 
reaction vessel. 
4.2.5 Influence of RESS processing on particle morphology 
Figure 27 shows the SEM photographs of tolbutamide particles. The intact tolbutamide particles 
were large irregular-shaped agglomerates (Figure 27a). Some huge agglomerates were broken by 
the mechanical grinding, but the particle size stayed large (Figure 27b). Particles prepared by the 
RESS processing were small homogeneous thin-plates regardless of the polymorphic form 
(Figure 27c: Form I; Figure 27d: Form II). 
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Figure 27 SEM photographs of tolbutamide. a: intact. b: ground for 30 min by using a vibration rod mill. 
c: RESS-processed at extraction conditions of 18 MPa and 80 °C. d: RESS-processed at 
extraction conditions of 26 MPa and 32 °C. 
 
Figure 28 shows the SEM photographs of barbital particles. The intact barbital particles were 
large polyhedral crystals (Figure 28a). The mechanical grinding had only slight effect on the 
morphology (Figure 28b). Form II particles prepared by the RESS processing were small needles 
(Figure 28c & Figure 28d), even some large particles were seen. These observations were in 
agreement with the size distribution, where two peaks at around 0.7 and 6 µm were seen (Figure 
28c & Figure 28d). The reason for this phenomenon has not been clarified yet. 
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Figure 28 SEM photographs of barbital. a: intact. b: ground for 30 min by using a vibration rod mill. c: 
RESS-processed at extraction conditions of 18 MPa and 60 °C. d: RESS-processed at extraction 
conditions of 26 MPa and 32 °C. 
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5. CONCLUSIONS 
The RESS processing was successfully applied to tolbutamide and barbital to produce 
micronized particles. Significant size reduction to micron or sub-micron level with narrow size 
distribution was achieved, while conventional mechanical grinding had only slight effect. 
The particle size was greatly affected by the extraction conditions. It was found for both drugs 
that the lower the extraction temperature was, the smaller was the mean particle size. Higher 
extraction pressure resulted in smaller mean particle size when compared at the same extraction 
temperature. It was possible to reduce the mean particle size of tolbutamide (126 µm) and 
barbital (204 µm) to 1.64 and 0.69 µm, respectively. 
The size reduction effect was further optimized using barbital by varying the expansion 
conditions. The mean particle size was reduced by lowering the spray nozzle temperature, by 
lowering the expansion chamber temperature, by increasing the CO2 amount per spray, and by 
increasing the exhaust gas flow rate. The mean particle size of barbital was successfully reduced 
to 0.54 µm by the process optimization. 
The RESS processing realized not only the micronization but the polymorphic conversion as 
well. As for tolbutamide, three polymorphs (Forms I, II and IV) out of four could be produced by 
changing the extraction conditions, and in the case of barbital one polymorph (Form II) out of 
three was produced consistently. 
The RESS processing proved to be a promising method to improve the bioavailability of poorly 
water-soluble drugs due to the significant size reduction effect and the polymorphic conversion 
to the metastable form. The method offers an attractive alternative to contribute green chemistry. 
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